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Introduction 
INTRODUCTION 
Health care is a rapidly developing field in which new technologies are 
introduced continuously. Not all new technologies have the same impact however: 
most represent only small changes in existing technologies, whereas only a few -
like organ transplants - really are revolutionary new developments. Some of these 
new technologies eventually lead to an improved health status or to an increased 
survival probability. But, unfortunately, over the years the introduction and 
application of new technologies has also led to a steady expansion of the budget 
necessary to maintain the ever increasing level of health care in most Western 
countries. Therefore, concern about costs nowadays plays an increasing role in 
many decisions surrounding the use and implementation of medical 
interventions.'·2 Whereas in the past technologies were introduced liberally, or after 
an assessment of merely efficacy or effectiveness, nowadays often more extensive 
research is done into all consequences, also in terms of costs, before a technology 
is implemented on a wide scale. 
Medical technology assessment (MTA) , which is a process of policy research 
in which the short and long term consequences of individual medical technologies 
are examined,3 can help in making decisions on the implementation of medical 
technologies. The information produced by such assessment can be used by policy 
makers in formulating regulations and legislation, by industry in developing 
products, by health professionals in treating and serving patients, and by health 
consumers in making personal heallh decisions. Such technology assessments 
may contain information on, amongst others, the ethical and legal consequences of 
the new technology. But the core of almost every MTA is formed by a cost-
effectiveness analysis (CE-analysis), in which the costs and effects of the 
technology are weighed against those of the best alternative treatment. 
For the assessment of the costs and effects of medical technologies, relative 
to the best alternative treatment, double blind randomised controlled trials (RCTs) 
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in which data on both costs and effects are collected, are often advocated."· 
However, performing a RCT is not always possible, ethical, or feasible: 
• In the evaluation of surgical techniques randomisation can be performed, but 
blinding is, of course, impossible. 
• In the evaluation of techniques which may be life saving - like liver 
transplantation or neonatal extracorporeal membranous oxygenation (ECMO) -
randomisation is soon thought to be unethical· 
• And, performing a randomised controlled double blind trial for every minor 
change in technology is time consuming and costly, and therefore not always 
feasible. 
In addition to this, it should be kept in mind that RCTs may support cost-efficacy 
analysis rather than cost-effectiveness analysis, because of the strict inclusion 
criteria that are frequently applied 5 .• 
In this thesis the role modelling may have in MTA is discussed and illustrated 
with examples. A model of a system or process can be defined, in general, as a 
theoretical description that can help to understand how the system or process 
works, or how it might work.'o In the following chapters mathematical modelling is 
used as a method to combine information from different sources into one coherent 
entity. There are many mathematical modelling techniques available, amongst 
which decision tree analysis, Markov processes and microsimulation are the most 
popular. Especially in the absence of a RCT modelling may be an efficient way to 
improve knowledge on a medical technology. It may also help to support the 
implementation of the results from RCTs or to extrapolate the results of a RCT to a 
more extended period of time or to a country with a different health care system." 
And, sometimes modelling may simply represent the best option because it may 
lead to reliable answers much faster than any RCT ever could. 
Whereas medical technology assessment nowadays frequently runs parallel 
with the introduction phases of a new technology, so does modelling. Modelling 
can be useful: 
• in the development of a technology, in order to evaluate whether introduction 
would be necessary and/or feasible, 
• in the evaluation phase of the technology, alongside its introduction, to assess 
efficacy and effectiveness, and 
• in the implementation phase, e.g. to assess the number of treatment facilities 
that would be needed to provide an adequate level of care all over the country. 
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Table 1 gives an overview of the relation between modelling and RCTs, 
showing that modelling can be used in: 
• the preparatory phase of a RCT, in the design of a cost-effectiveness study 
• in cases where a RCT can not be fully realised; as sUbstitution for part(s) of the 
trial 
• to complement RCT results with cost data 
• in the extrapolation of trial results and 
• in the implementation of results of a trial or a cost-effectiveness study. 
The application of modelling for these separate indications will be discussed below. 
Modelling can be used in the preparatory phase of a RCT to give some 
impression on whether cost-effectiveness analysis would be relevant, and to make 
an inventory of the important issues about to come up in the final analysis. In this 
situation modelling is performed as part of the design of the RCT. To obtain results 
quickly most models from this category are based on data from literature, expert 
opinion and I or easily available retrospective data from medical records. 
Another application of modelling in the preparatory phase lies in the development 
of methods needed in the subsequent RCT. If, for instance, clinical information is 
thought to be of importance in the analysis of the costs and effects of technologies 
or strategies, some kind of formalisation of this information is necessary. Modelling 
techniques can be used to include this information in the analysis. For example, in 
the analysis of the use of exercise tomographic thallium imaging in the diagnosis of 
severe coronary artery disease, clinical information was formalised by multivariate 
logistic regression,12 and in the evaluation of costs and effects of Intensive Care 
facilities clinical information was combined into a model to predict mortality.13 
And finally, modelling may be used to select the most cost-effective strategy from 
many possible (diagnostic) strategies. This can be done by modelling the results of 
a cohort study. Subsequently the most cost-effective strategy can be compared to 
the prevailing strategy in one prospective RCT. This approach may lead to faster 
results, at lower costs, than performing a large amount of RCTs, one for every 
strategy. With this method the most cost-effective strategy in the diagnosis of 
acoustic neuroma was found'· 
In situations where RCTs are not (fully) feasible, modelling can be used to 
substitute for part(s) of the trial, or sometimes even for the whole trial. 
In the evaluation of screening and prevention programmes modelling can be used 
to incorporate events in the future or rare - but important or expensive - events, that 
may be prevented by the programme, in the analysis. Models in this category often 
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combine data from cohort studies, epidemiological data and data from literature. 
Whereas trials for these programmes would require large patient populations or a 
very long follow-up, by modelling evaluations can be performed that would 
otherwise be unfeasible or too costly. 
In situations were a RCT is feasible, practical and financial aspects always limit the 
RCT to a finite time period and number of patients. Here modelling may allow for 
the inclusion of rare events or events occurring in the period after completion of the 
trial. 
In the evaluation of costs and effects of interventions in very rare diseases it is 
almost impossible to realise a RCT. In this situation modelling can be used to 
combine data from literature, and sometimes a small cohort study, to replace the 
whole RCT. This approach was used in the evaluation of post-exposure 
vaccination in rabies." 
And in the evaluation of technologies which may be life saving in the end stage of a 
disease, where no alternative treatment is available and where randomisation is 
thought to be unethical, like liver transplantation, modelling techniques can be used 
to construct a control group.'6 In this situation data from a cohort of patients treated 
with the new technology are used in combination with either data from literature, 
from historical controls or from patients from other centres or other countries. 
Sometimes a RCT has already been performed to prove the efficacy of the 
technology under evaluation without including detailed cost analysis. If 
subsequently a cost-effectiveness analysis is to be performed, modelling can be 
used to complement the results of such trials with cost data. 
Modelling can also be applied to extrapolate the trial results in order to enable 
a reliable assessment of cost-effectiveness. 
If more than one trial has already been performed modelling can be used to 
combine the results of these trials '1 This approach is often seen in 
pharmacoeconomic evaluations. For example in the evaluation of the efficacy of 
ACE-inhibitors in the treatment of heart failure several large multinational trials 
have been performed in only slightly different patient popUlations. In a subsequent 
cost-effectiveness analysis the results of these trials were synthesised by 
modelling techniques. 17 
Trials which are only designed to prove the efficacy of a new technology often use 
outcomes, like gastric ulcers prevented, that need translation into outcomes that 
are useful for CE-analysis, like QAL Ys or life years saved.··"·1 •. 19 Modelling, based 
on epidemiological data or data from literature, can be used for this translation. 
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Often trials use a time horizon which is too short for an appropriate estimation of 
cost-effectiveness,a,ll"a,2o Modelling, incorporating, again, epidemiological data 
and data from literature, can be used to perform the extrapolation from fixed 
observation time to life-time costs and effects, 
In addition to the extrapolations mentioned above, modelling can be applied to 
transform a cost-efficacy analysis into a cost-effectiveness analysis,?,ll"a,2o and to 
extrapolate results across indication groups or across trial settings or countries"a 
Table 1 The relation between modelling and RCTs 
Preparatory study 
Modelling to identify imporlant variables to be considered in the prospective cost-
effectiveness study, and to get an impression of the outcomes to be expected 
Method developmen/, e,g, modelling to optimise the information gained from clinical 
observations, 
Evaluation of strategies in order to select the strategies to be compared in the RCT 
Substitution for (parts of) trials that can not be performed because they are thought to be 
unethical, unfeasible or impossible 
Cost-effectiveness analysis of screening and prevention programmes focused on 
prohibiting rare events or events in the far future 
Incorporation of relatively rare events, or events occurring in the period alter 
completion of the trial 
Cost-effectiveness analysis for diseases with a low prevalence or incidence 
Modelling of the control group 
Complementation of trial results with cost data 
Extrapolation of trial results 
Meta-analysis of resulls of similar clinical trials to enable estimation of a reliable cost-
effectiveness ratio 
Extrapolation of intermediate trial outcomes to linal outcomes for cost-effectiveness 
analysis (in terms of QAL Ys or life years gained) 
Extrapolation of trial resulls to a longer period 
Transformation of a cost-efficacy analysis into a cost-effectiveness analysis 
Extrapolation of trial resulls to countries with a different heallh care system, different 
treatment patterns and/or different unit prices 
Implementation of the results of a trial or a cost-effectiveness analysis 
Macro~economic consequences of the introduction of a new technology 
Analysis of the need for (additional) treatment facilities, resource allocation 
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Modelling can also be used to support the actual implementation of a new 
technology. Here decision makers are interested, not only in information about the 
cost-effectiveness of a new technology, but also in the macroeconomic 
consequences of the introduction of the technology. Modelling techniques, 
incorporating information from various sources, can help to make an estimation of 
the consequences of introducing a technology on a nation-wide scale. 
And, finally, modelling techniques derived from operations research can be used in 
resource allocation, e.g. to evaluate the consequences of the introduction of 
additional treatment facilities:"" 
Table 1 shows that modelling may have a place in many different phases of a 
medical technology assessment. This table aims at giving an overview of the many 
possible applications in modelling in relation to RCTs. However, the categories 
should not be taken too strict and are not always mutually exclusive. Many cost-
effectiveness analyses can be ascribed to more than one category. For example, if 
the results of a trial are extrapolated, often more than one extrapolation is done. 
And sometimes the boundaries between categories are unclear, for example the 
difference between a preparatory study based on a large number of trials published 
in literature and an extrapolation of trial results through meta-analysis of a limited 
number of similar trials often is only gradual. 
That modelling in theory is already closely associated with the concept of 
cost-effectiveness analysis is illustrated by the fact that the author of a recent 
editorial on this subject, that was published in the New England Journal, assumed 
that modelling techniques were applied in gjj cost-effectiveness analyses'·'··29 
However, in practice modelled cost-effectiveness analysis still only comprises a 
very small part of medical literature. A MEDLINE survey shows that only 5.3% of 
the more than 350,000 registered publications for 1994 mention the word "model" 
(or modelling) in either tilie, abstract or subject heading, 0.5% the word "costs", and 
0.1% the word "cost-effectiveness". Only 135 publications mention both "costs" and 
"model" (0.04%) and only 57 the words "cost-effectiveness" and "model" (0.02%). 
Thirteen of these 57 articles use the word model in an other context or do not 
actually present a cost-effectiveness analysis, three were review articles. Table 2 
gives an overview of the remaining 41 articles. Modelling techniques seem to be 
especially popular for cost-effectiveness analysis in screening, prevention or 
vaccination programmes. Most of the other studies are preparatory studies, 
designed to give a "quick and dirty" impression of the costs and effects that are to 
be expected after introduction of a new technology. However, it looks like only few 
6 
Introduction 
of these studies will actually be followed by a RCT. There were no studies among 
the 41 that described the incorporation of rare events in a RCT, or a cohort study 
with a modelled control group. None of the studies was devised to convert a cost-
efficacy analysis into a cost-effectiveness analysis. Decision tree analysis appears 
to be the most popular modelling technique, featuring in 20 of the analyses, 
probably because of the general availability of decision analytic software. 
As stated before, the purpose of this thesis is to illustrate the use of modelling 
techniques in different phases of a medical technology assessment, and therefore 
also in different phases of the introduction of a medical technology, to discuss the 
relation between modelling and RCTs, and to illustrate some of the many different 
techniques that can be used in modelling. 
In chapter 1 an example is given of a modelling approach that was used as a 
preparatory study for a randomised controlled trial. In 1993, parties in the health 
care sector in the Netherlands were discussing the introduction of helicopter 
medical crews for the treatment of seriously wounded trauma victims. In this 
discussion both supporters and adversaries being so convinced of their own point 
of view deemed a randomised controlled trial to study the cost-effectiveness of this 
new facility as unnecessary. They assumed the facility evidently would -
respectively wouldn't - be cost-effective. To shed more light on this rather dark 
field, a "quick and dirty" modelling approach was chosen to evaluate whether the 
facility would be cost-effective and whether a RCT would be necessary. 
Chapter 2 gives an example of a modelling technique used to formalise 
clinical information in patients with suspected pulmonary embolism. Especially in 
pulmonary embolism many unspecific clinical items - like cough, shortness of 
breath, tachycardia - raise the suspicion of the presence of pulmonary embolism. It 
was thought that structuring this information into a clinical decision rule could lead 
to cost-savings and an improved diagnosis. 
Subsequently, the optimal place of this clinical decision rule within the diagnostic 
strategy was sought in a cost-effectiveness analysis, which is presented in chapter 
3. In this chapter the use of a decision model in the evaluation of the costs and 
effects of several diagnostic strategies is illustrated. The model permits the 
evaluation and comparison of the costs and effects of an almost unlimited number 
of diagnostic strategies. 
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Introduction 
In chapter 4 the use of a modelling technique to "make-up" for the absence of 
a control group is illustrated with an example in liver transplantation. In the 
evaluation of the cost-effectiveness of liver transplantation in the Netherlands a 
RCT was thought to be unethical, because in the USA it was already accepted (but 
not proven!) that transplantation could lead to an improved survival probability in 
patients for whom little alternative treatment was available. In the Dutch cost-
effectiveness study an adapted design was chosen. Liver transplantation was 
introduced on a limited scale and both costs and survival were monitored. To prove 
the effectiveness of the transplantation a Cox regression model was used to predict 
survival as it would have been without transplantation. In chapter 4A the technique, 
ils limits and alternatives are discussed more in detail. In chapter 4B the use of the 
technique in the cost-effectiveness analysis of liver transplanlation is illustrated. 
Chapter 5 illustrates the use of modelling techniques in the complementation 
and extrapolation of trial results. Here a Markov model is used to extrapolate the 
results of a large multi-centre North-American trial, on the use of ACE-inhibitors for 
patients with asymptomatic left ventricular dysfunction, to the Netherlands'"? The 
trial results were complemented with cost data specific for the Dutch situation. 
Also, an extrapolation of the results to a longer treatment period was made (20 
years instead of 4 years). Part of the translation from cost-efficacy analysis to cost-
effectiveness analysis was made by introducing the Dutch treatment policy in 
clinical practice as the best alternative treatment instead of the placebo treatment 
used in the original trial. 
In this chapter also the use of modelling techniques for the evaluation of the 
macroeconomic consequences of the introduction of ACE-inhibitors as preventive 
therapy is shown. 
Finally, chapter 6 illustrates the use of a model in the planning of neonatal 
ECMO facilities in the Netherlands. Instead of introducing treatment facilities on a 
trial and error basis, microsimulation was used to predict the number of patients 
that would have to be referred to centres abroad, relative to the number of 
treatment facilities and the number of neonates requiring treatment annually. 
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Chapter 1. Preparatory phase: design of a cost·effectiveness study 
IS USE OF HELICOPTERS WITH MEDICAL CREWS FOR 
SERIOUSLY INJURED ACCIDENT VICTIMS COST-EFFECTIVE IN 
THE NETHERLANDS? A MODELLING APPROACH' 
Summary 
In this chapter the cost-effectiveness of helicopter medical crews for patients 
with major trauma in the Dutch situation is assessed. For this assessment a 
modelling approach is used, combining available information with plausible 
assumptions. First, a base-line scenario is developed, implementing information 
that is available in the literature and a few assumptions. Next, the sensitivity of the 
cost-effectiveness for the various assumptions is evaluated in alternative 
scenarios. For the separate scenarios the relation between the costs per life year 
gained and the expected increase in the number of patients surviving an accident 
is established. In the base-line scenario the number of victims with a trauma score 
,; 12 is estimated at 4500 per year, it is assumed that victims who die at the scene 
of the accident are unsalvageable and that hospital treatment costs DFL 27,000 
per patient. As a result costs per life year saved are only under DFL 50,000 when 
more than 29 patients per year (9.23% gain in survival) are additionally saved. 
Sensitivity analysis shows that the cost-effectiveness depends highly on the 
expected gain in survival and on the estimate of the costs of hospital treatment. 
Both variables are surrounded with a lot of uncertainty. The model shows that, 
relying on the information that is available at this moment, no definite conclusions 
can be drawn on the cost-effectiveness of this facility, because too many essential 
data are miSSing. Empirical research is necessary . 
• Based on: Michel BC, Haul BA van. Is hel inzeUen van hetikoplers met een Iraumaleam bij ernstig gewonde 
angevalsslachloffers in Nederland Koslen-effectief? Een modelmatige benadering. Nedetfands Tijdschrift veer 
Geneeskunde 1994; 138(46): 2310·2315 
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Introduction 
Because the first hours after the accident are of vital interest to seriously 
injured accident victims, means to improve the medical assistance in this period are 
always searched for. In Germany the start of treatment for accident victims was 
shifted towards the scene of the accident several years ago. There, concurrently 
with an ambulance staffed by paramedics, a physician is sent to the scene of the 
accident by helicopter. '" The physician is charged with stabilising the patient. He 
(or she) also decides to what hospital the patient will be sent, and by which means 
of transport. In this system the helicopter is not primarily intended for the 
transportation of the patient, but mainly for the transportation of the physician. 
However, helicopter transportation of the patient is possible. 
THE PROBLEM 
Would helicopters with a medical crew be a welcome improvement to the 
current system in the Dutch situation? On the one hand there are some trauma 
specialists, supported by the ANWB, who answer this question affirmatively;6 on 
the other hand there is a letter from the former Secretary of State Simons to the 
Dutch Parliament in which the introduction of helicopters is called unnecessary.7 
Ideally the answer to this question should depend on the balance between costs 
and effects,5 .• and for a reliable assessment of this cost-effectiveness ratio 
empirical data are necessary. However, both supporters and adversaries of 
helicopters with medical crews implicitly assume that empirical research is 
superfluous, because they regard their own point of view as evident. In the 
modelling approach presented here, it is evaluated whether such peremptory 
statements can really be made, if one is to rely on the information that is currently 
available for the Dutch situation. 
THE ADDITIONAL VALUE OF A HELICOPTER WITH A MEDICAL CREW TO THE 
CURRENT SYSTEM 
A helicopter can supply medical assistance within a radius of 70 kilometres just 
as fast as an ambulance can in a radius of 15 kilometres. By helicopter a limited 
number of "trauma teams" can be employed to cover the whole of the Netherlands. 
18 
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Patients can be transported to specialised centres over larger distances and 
distributed over hospitals with more expertise: thereby probably diminishing the 
number of secondary transports. Also, it is likely that better adaptations for 
shortages in Intensive Care facilities in the region of the accident can be made. 
An additional advantage might be found in the number of trauma centres in the 
Netherlands. It is almost certain that these centres will eventually be installed, but 
the number, time-line and form are still under discussion:·,·?·,o.11 If helicopters are 
stationed at trauma centres, probably less than the 11 centres proposed by the 
College for Hospital Facilities (CHF) will be needed, because by helicopter patients 
can be transported to the centres over a larger distance.' 
Estimates 
In the estimates of costs and effects, in terms of Dutch Guilders and life years 
gained, data specific for the Netherlands are used whenever possible. If no data 
are available assumptions are made. All estimates are combined into a descriptive 
model in a computer spreadsheet programme (Quattro Pro, version 5.00, Borland 
International Inc.). In this model first the costs and effects are calculated for a 
baseline scenario. Subsequently the influence of the assumptions on the results is 
evaluated in alternative scenarios. 
ESTIMATE OF THE NUMBER OF ANNUAL FLIGHTS 
International publications show that patients with a trauma score less than or 
equal to 12 have a bad prognosis and might benefit from care in a speCialised 
centre, so maybe also from transportation by helicopter,..,2.'3.,. Therefore, the 
model is limited to these patients. Little data are available on the exact number of 
patients within this category. The CHF combines three separate estimates into a 
final estimate of 4500 seriously wounded trauma patients admitted into hospital 
each year.' 
To estimate the annual number of helicopter flights, accidents in which victims 
die at the scene of the accident should also be taken into account. According to the 
Central Bureau for Statistics 1280 persons died within 30 days of a traffic accident 
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in 1991, whereas 698 of these victims died at the scene of the accident. 15 
Publications by Draaisma state that the ratio of traffic accidents to other accidents 
is 81.4% to 18.6% in seriously injured patients.17 If the assumption is made that this 
ratio is identical for victims who die at the scene of the accident, an estimate of 
4500 + (698/0.814) = 5357 seriously or deadly injured accident victims results. 
It is assumed that the helicopter can be used only during daytime, in 
reasonable weather conditions, and outside city areas. The Central Bureau for 
Statistics reports that 29.5% of traffic accidents in which people are killed or 
transported to hospital take place during daytime outside the city area and that 
weather conditions are favourable for helicopter usage in 97.2% of the traffic 
accidents.15 Since corresponding figures for non-traffic accidents are unknown, it is 
assumed that the same percentages will apply. The potential number of accident 
victims for whom a helicopter can be used can therefore be estimated at 5357 x 
0.295 x 0.972 = 1537. Two hundred and forty six of these victims will die at the 
scene of the accident, before transportation to a hospital can take place. 
In practice, the helicopter is used rather frequently for patients who do not 
really need this kind of assistance. Data from the Austrian and German helicopter 
services show that respectively 7% (200/2874) en 25.2% (7893/31251) of their 
fiights were unnecessary.'6.'. In the model the average of these two percentages is 
included: 16.1%. 
If it is assumed that on average one seriously or deadly injured patient will be 
involved in every accident for which the helicopter is employed, it can be estimated 
that 1784 annual helicopter fiights will be made. 
ESTIMATE OF THE NUMBER OF LIFE YEARS GAINED 
The Dutch Central Bureau for Statistics publishes data on the age and sex of 
deceased traffic accident victims. '5 
Because death may only be declared after a personal inspection by a physician, 
who currently is not present at the scene of the accident,'9 it is plausible that 
victims registered as "deceased at the scene of the accident" can't be saved even 
by a helicopter with a medical crew. The Central Bureau for Statistics' accident 
statistics show that yearly 582 persons die within 30 days after a traffic accident, if 
deaths at the scene of the accident are excluded.'5 After correction for the time of 
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the accident - 73% of the fatal accidents take place in daylight or twilight -, the 
place of the accident - 60.6% outside the city area -, weather conditions - in 98% 
the weather conditions allow a helicopter flight -, and non-traffic accident victims, 
an estimate results of (582 x 0.73 x 0.606 x 0.98) I 0.814 = 310 deaths that might 
be prevented by a helicopter service. By relating these data to the average 
expected life-time for age category and sex, it can be estimated that 12641 life 
years may be saved by the helicopter service, 40.8 per deceased:o 
ESTIMATE OF THE COSTS 
The estimate of the costs of the helicopter service is based on a research 
project performed by the Rotterdam School of Management in 1987.21 The fixed 
costs per helicopter are estimated at DFL 2,030,000 annually (table I). The variable 
costs are estimated at DFL 750 per flight, for maintenance, fuel and (spare) parts. 
Table 1 Fixed cosls per ilelicopler 
Annual costs 
Rent helicopter DFL 450,000 
Insurance helicopter (6% of its value) DFL 250,000 
Insurance medical personnel DFL 100,000 
Communication-assistant DFL 50,000 
Training personnel DFL 50,000 
Hangar DFL 30,000 
Maintenance and other DFL 100,000 
Organisation DFL 100,000 
Communication devices DFL 50,000 
Two pilots (average salary DFL 125,000) DFL 250,000 
Medical personnel' DFL 600,000 
Tolal DFL 2,030,000 
a Two physicians (average salary DFL 200,000) and tv/o nurses (average salary DFL 100,000) 
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Because part of the effect of the use of helicopters is due to the treatment of 
patients in trauma centres instead of general hospitals, the costs of these centres 
are included in the calculations, but only as far as they can be attributed to patients 
in which the helicopter-service is involved. The CHF estimates that the 
establishment of 11 trauma centres will cost DFL 100,000,000 each year to acquire 
a fixed gain in survival of 25%4 In addition to the calculations of the CHF changes 
in costs due to changes in patient distribution are taken into account here. And it is 
assumed that, after the introduction of the helicopters, only five trauma centres 
need to be established (one per helicopter), and that for each of these five centres 
no more capital investments will be necessary than in a situation with eleven 
centres. The costs of hospital treatment for an accident victim are estimated by the 
CHF at DFL 27,000 to DFL 48,000. In the baseline scenario the lowest of these two 
amounts is used. 
In agreement with the assumptions of the CHF costs of treatment in general 
hospitals are estimated at 55% of the costs of treatment in trauma centres, and the 
costs of treatment for a patient who eventually dies at half of normal treatment 
costs. Also in accordance with the CHF, it is assumed that in the current situation 
already 25% of the patients are treated in hospitals comparable to trauma centres. 
Table 2 gives an overview of the separate scenarios. 
Table 2 Overview of the separate scenarios. The limit of cost-effectiveness is OFL 
50, 000 for all scenarios, there are 5 helicopters and the results are 
discounted by 5%. no. = number of patients; TS = trauma score; avg = 
average; late mortality = mortality more than 30 days aller the accident 
Scenario avg. costs can deceased no. with life expectancy late 
hospilal at scene TS'; 12 relative to age mortality 
treatment accident be annually and sex 
saved? 
Baseline j 27.000,- no 4500 100% 0% 
Scenario I j 48.000,- no 4500 100% 0% 
Scenario II j 27.000,- yes 4500 100% 0% 
Scenario III j 27.000,- no 3500 100% 0% 
Scenario IV j 27.000,- no 4500 75% 0% 
Scenario V j 27.000,- no 4500 100% 10% 
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Results 
The cost-effectiveness of a helicopter service for seriously injured trauma 
patients is expressed in additional costs per life year gained compared to the 
current situation. Both costs and life years gained are discounted by 5% annually, 
according to the guidelines for cost calculations in cost-effectiveness analysis.21 
This means that costs and effects in the far future are given less weight than costs 
and effects in the near future. 
For the Netherlands, a nation-wide service can probably be provided with five 
helicopters.22 Total fixed costs will amount to DFL 10,150,000. Variable costs will 
depend on the number of flights, and will amount to approximately DFL 1,338,000, 
if 1784 annual flights are performed. To these costs, costs for treatment in 
specialised centres, partly depending on the percentage of patients surviving, are 
added. 
Figure 1 Number of deceased to be saved in the separate scenarios in order to attain 
a cerlain cost-effectiveness r8Iio.(- baseline; - - - ::: scenario /; - - - - - ::: 
scenario 1/; - - - - ::: scenario 11/; - ::: scenario IV; - - - - - - ::: scenario V) 
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If all deaths could be prevented by the helicopter service the cost-
effectiveness would be most favourable: DFL 5.074,- per life year gained. 
However, it is reasonable to assume that part of the mortality after accidents can 
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never be prevented. Figure 1 shows the cost-effectiveness in Dutch Guilders per 
life year saved for different numbers of deaths prevented by the helicopter service, 
as compared to the current situation. The limit of DFL 50,000 per life year saved, 
that was considered cost-effective in, for example, kidney-function-replacing 
therapy, and heart and liver transplantation,23-25 is reached if the helicopter service 
will be life-saving in 29 persons annually. Table 3 gives a summary of the results 
and a comparison to the current situation. 
Table 3 Costs in the baseline scenario (gain in sUlvival 9.23%) compared to the 
current situation in millions Dutch Guilders. (no. = number of patients) 
Patients in trauma centre: survivors 
Patients in trauma centre: dead < 30 days 
Capital investment 
Total costs treatment in trauma centres 
Patients in general hospital: survivors 
Patients in general hospital: dead < 30 days 
Total costs treatment in general hospital 
Tolal cosls 
SENSITIVITY ANALYSIS 
current situation after introduction 
helicopters 
no. pat costs no. pat costs 
262 
44 
768 
151 
7.1 
0.6 
7.7 
11.4 
1.1 
12.5 
20.2 
1048 
177 2.4 
1.9 
32.6 
32.6 
The influence of the simplifications and assumptions that were used in the 
baseline model is tested in some alternative scenarios. Differences to the baseline 
scenario are shown in table 2, results in table 4. In the presentation of the results a 
preferred cost-effectiveness of DFL 50,000 per life year gained is used. 
The cost-effectiveness ratio is rather sensitive to the ave rag e costs of hospital 
treatment for trauma patients. In scenario I the largest of the two amounts stated by 
the CHF is used (DFL 48,000), in that case a much larger gain in survival must be 
attained to reach the limit for cost-effectiveness of DFL 50,000· In scenario II it is 
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assumed that victims who die at the scene of the accident can also be saved by 
the helicopter service. This does not result in a larger number of flights, but it does 
result in a larger number of hospital admissions. 
The results of scenario'" show that changes in the number of patients with a 
trauma score equal to or smaller than 12 only have a minor influence on the 
outcome. However, the number of additional treatments in a trauma centre is 
clearly smaller, 715 a year. 
In scenario IV it is assumed that life expectancy is shortened by 25%, due to 
remaining morbidity. In scenario V the assumption is made that in the period 
following 30 days after the accident, the registration period of the Central Bureau 
for Statistics, still 10% of the trauma patients will die and that these patients can be 
saved by better primary medical assistance. 
Finally,- the influence of the percentage of unnecessary flights on the cost-
effectiveness is evaluated. This influence appears to be very minor. Without 
unnecessary flights, with complete efficiency of the service, in the baseline 
scenario the limit of DFL 50,000 is attained if 28 persons are saved, whereas with 
50% unnecessary flights the limit is reached if 29 persons are saved. In this, 
however, no account is taken of the loss in efficiency that may occur if, by an 
increase in the number of flights, the number of simultaneous requests for 
helicopter assistance increases. 
The cost-effectiveness of the use of helicopters with a trauma team appears to 
depend strongly on the average costs of hospital treatment, and on the gain in 
survival that can be reached with this service (see figure 1). Other factors, like the 
annual number of patients presenting with a trauma score less than or equal to 12, 
the life expectancy, or the percentage of flights that are unnecessary turn out to be 
less important. 
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Table 4 Expected costs for society (in millions Dutch Guilders) attributed to the helicopter service, and minimum gain in survival 
necessary to obtain a cost-effectiveness ratio of DFL 50,000 per life year gained, for the separate scenarios. no. = 
number 
baseline scenario I scenario II scenario III scenario IV scenario V 
Extra patients in trauma centre 919 919 951 715 919 919 
Minimum gain in survival needed for cost- 9.23% 12.29% 4.85% 7.73% 10.24% 8.35% 
effectiveness 
No. of patients to be saved I no. deceased 29/310 38/310 28/574 24/310 321310 28/341 
considered salvageable 
Costs for 5 trauma centres 32.6 56.2 33.5 25.7 32.6 32.3 
Costs in current situation - 20.2 - 35.9 - 20.2 - 16.9 - 20.2 - 20.0 
Extra costs 5 trauma centres 12.4 20.3 13.3 8.8 12.4 12.3 
Costs 5 helicopters 11.5 11.5 11.5 11.2 11.5 11.5 
Total costs 23.9 31.8 24.8 20.0 23.9 23.8 
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Discussion 
In the absence of empirical research an attempt was made to model the cost-
effectiveness of the use of helicopters with medical crews using available data. In 
this approach several factors had to be left out of account because many data 
were unavailable. For instance, some patients might need shorter hospitalisation 
and have less remaining symptoms after helicopter assistance, due to the fast 
initiation of treatment' However, helicopter assistance might also keep patients 
who would have died otherwise alive in a bad condition, causing long 
hospilalisations in nursing homes or rehabilitation centres.· The (financial) 
consequences of a decrease in the number of secondary transports were also left 
out of account. In the current analysis the indirect costs, like loss of production for 
society due to illness, disablement and death were not included. Conform the 
guidelines for cost calculations in health care research this is allowed if it is to be 
expected that the period of sick-leave will be longer than the "friction period" in all 
scenarios. 21 This friction-period represents the period between the employee 
dropping out and his or her replacement from inside or outside the company.'6 In 
the Netherlands this friction period was 96 days on average in 1990." The average 
sick-leave for fractures due to traffic accidents was longer, on average 
approximately 126 days. ,. This last figure is not corrected for the level of trauma, 
for poly trauma palients the period will probably be longer. Therefore, the use of 
helicopters with medical crews will probably not make the period of production loss 
shorter than the friction period. Hence, it is not to be expected that net yields in 
production will occur. 
In the current analysis it is estimated that, in the baseline scenario, 29 extra 
patients will have to survive compared to the current situation to make the service 
cost-effective, if DFL 50,000 is accepted as the limit for cost-effectiveness. 
Irrespective of the question whether the assumptions on which this scenario is 
based are correct - which is not certain because of the scarcity of data - the 
question presents itself whether such favourable effects can actually be attained in 
practice. 
In the estimalion of the gain in survival that can be expected to occur, it is 
important to realise that not all in-hospital deaths in seriously wounded accident 
victims can be prevented.'9 Several papers were published about the gain in 
su~!ival that can be reached by treatment in trauma centres. Virtually all reported 
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an improvement in survival. 30-34 Partly because these publications were based on 
comparisons of mortality before and after introduction of trauma centres, simple 
conclusions about the percentage improvement in survival are difficult to reach. In 
the Netherlands the number of persons who died at the scene of a traffic accident 
or within 30 days of the accident decreased by approximately 48% between 1976 
and 1991. 15 If a trauma centre would have been founded in the Netherlands in 
1976 an imaginary effectiveness of this centre would have been shown. In such 
dynamic processes it is very difficult to assess the effectiveness of services and 
changes in policy in a reliable way. 
Also, the maximum gain in survival that can be attained for extramural mortality 
is uncertaina5.36 In the Netherlands ambulance-nurses are well educated and 
highly experienced. Because of the ever increasing use of protocols, they also 
have a large competence. The medical interventions that can be performed at the 
scene of the accident and during transport are limited, due to the primitive 
circumstances.'·8.19 A physician might only be able to set a better indication for 
performing or omitting certain actions. Comparisons of helicopter services staffed 
by physicians with helicopter services staffed by paramedics, do not always show 
better results.37.38.39.40 
The above illustrates that the factual improvement in survival that can be 
obtained by a helicopter service with a medical crew is unknown. From the data 
that are currently available it can not be inferred whether such a service would be 
cost-effective in the Netherlands. Too many data are missing to make peremptory 
statements. Especially data on the costs of hospital admissions for seriously 
wounded trauma patients, the relation between certain forms of medical assistance 
and the final quality of life of the patient, and data on intramural and extramural 
preventable mortality are missing. The results presented here leave enough room 
for doubt to contradict supporters of the service, who say that the cost-
effectiveness is so evident that further research is not needed. But adversaries, 
who say that helicopters with a medical crews are unnecessary in the Dutch 
situation are not proved right either. 
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Chapter 2. Preparatory phase: method development 
THE ROLE OF A CLINICAL DECISION RULE IN SYMPTOMATIC 
PULMONARY EMBOLISM PATIENTS WITH A NON-HIGH 
PROBABILITY VENTILATION-PERFUSION SCAN' 
Summary 
In this chapter the construction of a simple, quantitative clinical decisIon rule 
(CDR) for the diagnosis of pulmonary embolism (PE) in patients with a non-high 
probability ventilation-perfusion scan is illustrated. The CDR was constructed by 
multivariate stepwise logistic regression analysis on 28 clinical and lung scan items 
gathered prospectively and independently in consecutive symptomatic patients. Data 
on 140 consecutive patients admitted to the Academic Medical Centre and the 
Slotervaari Hospital in Amsterdam who had a non-high probability result of the 
ventilation perfusion scan and an interpretable pulmonary angiogram were used. The 
prevalence of a proven pulmonary embolism was 27.1%. A clinical decision rule 
containing the presence of wheezing, previous deep venous thrombosis, recently 
developed or worsened cough, body temperature above 37'C and multiple defects 
on the perfusion scan was constructed. For the clinical decision rule the area under 
the Receiver Operating Characteristic (ROC) curve was larger than that of the prior 
probability of pulmonary embolism as assessed by the physician before lung-' 
scanning. (0. 76 versus 0.59; p = 0.0097) At the cut-oft point with the maximal positive 
predictive value 2% of the patients scored positive, at the cut-oft point with the 
maximal negative predictive value pulmonary embolism could be excluded in 16% of 
the patients. The optimal use of the rule appears to be in the exclusion of PE. 
Prospective validation of this rule is indicated to can finn its clinical utility . 
• Based on: Michel Be, Kuijer PMM, McDonne!l J, Beek EJR van, Rutten FFH, BOiler HR. The deriVation of a 
clinical decision rule in symptomatic pulmonary embolism patients with a non-high probability venlitation-
perfusion scan. Submitted. 
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Introduction 
Ventilation-perfusion lung scanning is a reliable and frequently used 
diagnostic method in patients with clinically suspected pulmonary embolism. 
Therapeutic decisions can be based on a negative or high probability resull. 
However, in more than 40% of the patients a non-high probability scan result is 
obtained. To confirm or exclude the presence of pulmonary embolism in these 
patients, of whom 20 to 30% have the disease, can be very difficull.' For this goal 
multiple diagnostic tests, including serial noninvasive leg testing for venous 
thrombosis, pulmonary angiography, blood tests for the detection of coagulation 
activation and clinical assessment, are advocated:"" 
Recently, it was shown that the addition of clinical assessment to the interpre-
tation of lung scan results can increase the diagnostic accuracy for pulmonary 
embolism.,,5 Since the clinical information in that study was, however, gathered in 
an unstandardised fashion, the reproducibility of the results may be hampered. In 
general there is considerable variation among physicians in the way clinical 
information is utilised in the diagnostic process of pulmonary embolism." Since this 
variation does not seem to decrease with increased experience of the physician, 
training will probably not improve the use of this information6 Standardising the 
clinical assessment appears to be the best solution. Several investigators have 
tried to derive clinical decision rules in order to reach such standardisation.7-9 
These decision rules generally contain a number of clinical items, each with a 
weight indicating their predictive value for the presence or absence of pulmonary 
embolism. After the weighted scores of the items have been aggregated in a total 
score, the clinical decision rule can be used like a laboratory test: if the total score 
is above a certain level (the cut-off point), the presence of pulmonary embolism is 
highly likely, and on the other hand if it is below a certain level, the presence of 
pulmonary embolism is virtually excluded. However, to make these decision rules 
reliable and easy to use in a clinical selting, they should only include reproducible 
items that can be obtained in a simple way. None of the available decision rules 
meets these criteria. 
The aim of our prospective study in consecutive symptomatic patients was to 
derive a simple and easily reproducible clinical decision rule that can improve the 
current use of diagnostic information in patients with a non-high probability result of 
the ventilation-perfusion scan. 
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Patients and methods 
PATIENTS 
Of 452 consecutive patients with clinically suspected pulmonary embolism 
who participated in a prospective clinical study in the Academic Medical Centre and 
the Siotervaart Hospital in Amsterdam, the Netherlands, a clinical registration form 
was completed by the physician directly in charge of the patient. Only data on 
patients with a subsequent non-high probability ventilation-perfusion scan and an 
interpretable pulmonary angiogram were used to construct the clinical decision 
rule. After the recording of the history, physical examination, chest X-ray and 
routine laboratory tests, but before lung scanning, the same physician was asked 
to score the patient's probability of having pulmonary embolism as less than 10%, 
10 to 50%, 50 to 90%, or more than 90%. 
CLINICAL DATA 
The clinical registration form contained questions on demographic 
characteristics, the present and past medical history and the physical examination. 
For the derivation of the clinical decision rule this information and data related to 
qualitative aspects of the perfusion scan (the presence of multiple defects and the 
presence of segmental defects) were used. Items on which only a small 
percentage of patients scored positive (e.g. leg paresis, recent plaster cast or 
childbirth), with a definition that was found to be unclear (e.g. a third or fourth heart· . 
sound, heart failure and apprehension/fear) or that had frequent missing data (e.g. 
length, weight and arterial blood gas analysis), indicating that the item was difficult 
to obtain in practice, were omitted from the analysis. After evaluation, 28 items 
were thought to be clearly defined and easily reproducible. These items were used 
to derive the clinical decision rule. 
DERIVATION OF THE CLINICAL DECISION RULE 
The clinical decision rule was based on a stepwise multiple logistic 
regression, with the result of the angiogram as the dependent variable. In such 
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regression analysis a combination of variables is sought that can optimally predict 
the presence or absence of, in this case, pulmonary embolism. Each variable is 
given a weight (the coefficient) to indicate its contribution to the prediction of 
pulmonary embolism. In the application of the rule each variable is scored by 
multiplying its coefficient by 1 if the variable is present or by a if the variable is 
absent. These scores and the constant are added to reach a total score. The 
adding of the constant is necessary because patients who have none of the 
variables in the analysis present will still have a certain chance of having a 
pulmonary embolism. Depending on the purpose of the rule a cut-off point is 
chosen above which the rule is called positive. If the rule is used to rule out 
pulmonary embolism, with a maximum level of certainty that the excluded patients 
indeed do not have pulmonary embolism (a maximum "negative predictive value"), 
a low cut-off point is chosen. On the other hand if the rule is used to rule in 
pulmonary embolism, with a maximum level of certainty that patients with a positive 
result indeed have pulmonary embolism (a maximum "positive predictive value"), a 
high cut-off point is chosen. Usually, in logistic regression the total scores 
mentioned above are transformed (by log-it transformation) to values between a 
and 1. To prevent difficult calculations, and to make the clinical decision rule more 
easily applicable in practice, we transformed the values of the cut-off points 
instead. 
In the derivation phase of a clinical decision rule it is important to assess 
whether the rule will be useful in clinical practice. This depends not only on the 
clarity of the definitions and on the reproducibility of the variables, but also on the 
stability of the rule in sub-sets of the patient population. This, of course, should be 
formally tested in a prospective validation study. Because such validation requires 
another clinical study, an attempt was made to assess the stability of the selected 
combination of variables in sub-sets of the patients in the current study. For this 
purpose, the weights of the variables in the clinical decision rule were recalculated 
by multiple logistic regression not on the full dataset but on a subset containing a 
random sample of 73% of these patients (the "derivation patients"). Sometimes 
derivation was impossible because too few patients with one of the variables 
present were included in the subset. For all rules that could be derived, the rule 
with its new coefficients was applied to the remaining 27% of the patients (the 
"validation patients") and it was evaluated how many of these patients were 
excluded or included at the points with the maximal positive and negative predictive 
value, and whether the exclusion or inclusion was correct. This process of 
"derivation" and subsequent "validation" was repeated 1000 times (using a 
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computer simulation model built in GUM 4 (The Numerical Algorithms Group Ltd, 
Oxford, United Kingdom)), each time with a new random selection of the sub-
population for "derivation" and "validation". 
STATISTICS 
Univariate significance was tested for the continuous variables by Student's 
two sample I-test for variables with a normal distribution or Mann-Whitney rank-
sum test for variables without a normal distribution and by Fisher's exact test for 
the discrete variables. Significance for the Receiver Operating Characteristic 
curves was tested by the method described by Hanley and McNeil.'o All statistical 
analyses were performed in BMDP statistical software release 1990 (BMDP 
Statistical Software, Los Angeles, California, United States of America). 
Results 
PATIENTS 
A non-high probability result of the ventilation-perfusion scan was obtained in 
186 of the 452 consecutive patients (41.2%). In 40 of these patients, pulmonary 
angiography could not be performed because of heart failure (8 patients), severe 
pulmonary hypertension (4 patients), poor clinical condition (11 patients), renal 
failure (3 patients), thrombocytopenia (3 patients), patient's refusal (7 patients), 
initial misdiagnosis of the scan (3 patients) or logistic reasons (1 patient). In a 
further 6 patients the result of the angiogram was non-interpretable. Data 
concerning the remaining 140 patients were used to construct the rule. The mean 
age of these patients was 57.7 years (SO 17.0), half were males, 60% were seen 
initially as outpatients. Patients had had symptoms for a median of 2.5 days before 
entering the diagnostic process. On the angiogram, 38 patients (27.1 %) had 
evidence of pulmonary embolism. 
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Table 1 Prevalence of the studied variables from the medical history, physical 
examination and lung scan findings in the 140 patients with a non-high 
probability lung scan and an interpretable angiogram. 
Variable PE' PE P-
absent present value 
N = 102b n = 38 
Medical historyC Sanguineous sputum 6.9% 21.1% 0.03 
Cough, new or recently worsened 26.7% 44.7% 0.06 
COPDd 33.3% 18.4% 0.10 
Previous deep venous thrombosis 5.9% 13.2% 0.17 
Surgery within the past 3 months 18.6% 7.9% 0.19 
Days of immobilisation 0.0' 0.0' 0.25 
Malignancy 27.5% 21.1% 0.52 
Gender (percentage male) 52.9% 47.7% 0.57 
Dyspnoea 19.6% 23.7% 0.64 
Previous pulmonary embolism 8.8% 5.3% 0.73 
Palpitations 16.7% 13.2% 0.80 
Days wilh symptoms 2.0' 3.0' 0.81 
Age 57.8' 57.6' 0.93 
Family history of thrombosis 12.7% 10.5% 1.00 
Collapse 4.9% 5.3% 1.00 
Green sputum 7.8% 7.9% 1.00 
Physical examinationc Wheezing 24.5% 5.3% 0.01 
Body temperature above 37" Celsius 40.2% 60.5% 0.04 
Pleural rub 15.7% 28.9% 0.09 
Breath frequency, in breathslmin 19.3' 21.7' 0.11 
Leg paresis 2.9% 7.9% 0.34 
Crepitations 37.3% 42.1% 0.70 
Increased central venous pressure 10.8% 13.2% 0.77 
Quetelet-index 24.1' 24.0' 0.86 
Heart frequency, in beatslmin 93.0' 92.5' 0.90 
Signs of OW 9.8% 10.5% 1.00 
Perfusion lungscanC Multiple defects on perfusion scan 71.6% 83.3% 0.19 
Segmental defects on perfusion scan 55.9% 61.1% 0.70 
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Legend to table 1: 'PE = pulmonary embolism as classified by pulmonary angiography; b 
n = number of patients; C percentage of patients wilh variable present; d chronic obstructive 
pulmonary disease; , median; I average; 9 deep venous thrombosis 
CLINICAL DECISION RULE 
Most of the investigated variables showed no significant difference for 
patients with or without pulmonary embolism, table 1. Only body temperature 
above 37' Celsius and sanguineous sputum were present significantly more often 
in patients with pulmonary embolism than in those without (p < 0.05). Wheezing 
was more frequent in those shown not to have pulmonary embolism (p = 0.01). 
In the multivariate stepwise logistic regression, the absence of wheezing, 
previous deep venous thrombosis, a new or recently worsened cough, a body 
temperature above 37' Celsius and multiple defects on the perfusion scan were 
identified as the optimal combination of predicting variables for the presence or 
absence of pulmonary embolism, table 2. The five selected items each have a 
weight in predicting the presence or absence of pulmonary embolism in this 
combination of variables (expressed in the coefficient). The rule is applied by 
adding the coefficients for the items present and the constant, returning a total 
score. 
Table 2 The combination of variables from Ihe medical history, physical examination 
and lung scan resul/s that has optimal predictive value for Ihe presence or 
absence of pulmonary embolism in the regression analysis 
Variable Coefficient Standard error P-value 
Wheezing -3.068 1.17 0.0002 
Previous deep venous thrombosis 1.886 0.841 0.0210 
Cough recently developed or worsened 0.9554 0.445 0.0314 
Body temperature above 37'C 0.8847 0.440 0.0413 
Multiple defects on perfusion scan 0.9828 0.550 0.0598 
Constant -2.455 0.607 
Addition of other variables known to be associated with pulmonary embolism, 
including sanguineous sputum, malignancy, collapse, signs of deep venous 
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thrombosis and a history of previous pulmonary embolism, or elimination of the 
weakest predictive variable in the combination, i.e. multiple defects on the 
perfusion scan, did not improve the predictive value of the rule. Comparison of the 
performance of the clinical decision rule to that of the prior clinical probability of 
pulmonary embolism as assessed by the patient's physician at admission, using 
Receiver Operating Characteristic curve analysis, shows that the clinical decision 
rule has a better sensitivity and specificity for every cut-off point, figure 1. 
Figure 1 ROC curve of the clinical decision rule (-.-.-.), compared to the ROC curve 
of the prior clinical probabilily as assessed at admission by the attending 
physician (-+-+-+) 
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The area under the curve is significantfy greater for the CDR than for the clinical 
assessment (0.76 vs. 0.59; P = 0.0097) 
If the rule is used to exclude patients without pulmonary embolism, aiming at 
a maximum level of certainty that the excluded patients indeed do not have 
pulmonary embolism, a maximum "negative predictive value" is sought for. A 
negative predictive value of 100% was reached at the transformed cut-off point of 
minus 2.512 (0.075 untransformed). Here, the test had a positive predictive value 
of 31%, a sensitivity of 100% and a specificity of 22%, table 3. This indicates that 
the rule can be used to exclude pulmonary embolism in 16% of the symptomatic 
patients with a non-high probability ventilation-perfusion scan. 
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If the rule is used to select patients with pulmonary embolism, with a 
maximum level of certainty that patients with a positive result indeed have 
pulmonary embolism, a maximum "positive predictive value" is sought for. The best 
positive predictive value that could be reached was 100%, at a transformed cut-off 
point of 0.405 (0.6 untransformed). At this point a negative predictive value, a 
sensitivity and a specificity of 75%,8% and 100% were obtained, respectively. This 
indicates that the rule is less useful for the selection of patients with pulmonary 
embolism, since only 2% of the patients with pulmonary embolism can be 
identified. 
Table 3. Results of Ihe clinical decision rule, based on dala from Ihe medical hislory, 
physical examination and lungscan findings in 140 patienls with a non-high 
probability lung scan and an inlerprelable angiogram, compared 10 Ihe 
findings on Ihe pulmonary angiogram for Ihe same patienls.' Numbers are 
numbers of patienls. 
rule used for Ihe exclusion of pE!' Pulmonary embolism 
clinical decision rule present absent total 
positive 36 79 115 
negative 0 22 22 
total 36 101 137 
rule used for Ihe selection of patienls with pi!' Pulmonary embolism 
clinical decision rule present absent total 
positive 3 0 3 
negative 33 101 134 
total 36 101 137 
, 3 patienls had a missing value for one of Ihe variables in Ihe rule and had 10 be excluded 
b cui-off poinl aimed al maximal negative predictive value of Ihe rule 
C cui-off poinl aimed al maximal positive predictive value of Ihe rule 
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STABILITY 
To assess the stability of the combination of variables in separate sub-
populations, the coefficients of the variables were estimated in a random selection 
of 100 "derivation patients" out of the 137 patients who did not have missing data 
for the variables included in the rule. Subsequently, the rule was "validated" for its 
usefulness in the exclusion of pulmonary embolism in the remaining 37 patients. 
Thousand random selections of subpopulations were made, containing in total 
100,000 "derivation" patients and 37,000 "validation" patients. The number of 
patients in whom pulmonary embolism was excluded by the rule in the separate 
selections of 37 "validation" patients varied between 1 and 17. In total, the rule 
indicated pulmonary embolism could be excluded in 15.7% (5801 patients) of the 
"validation" patients. Only 1.3% of these patients (77 patients) did have pulmonary 
embolism and were, therefore, incorrectly excluded. In conclusion, the chance that 
limited changes in the patient population in the prospective validation phase will 
render a clinical decision rule based on this combination of variables invalid seems 
small. 
DISCUSSION 
After a surge of interest for technical methods in the diagnosis of pulmonary 
embolism, there has recently been a revival of attention for the value of information 
contained in the medical history and physical examination.' Both clinical decision 
rules and neural networks have been advocated in the last few years. 8,9.11 
This study demonstrates that it is possible to construct a simple clinical 
decision rule that can be used in the diagnostic work-up of patients with suspected 
pulmonary embolism. If the current clinical decision rule is used to confirm 
pulmonary embolism in symptomatic patients with a non-high ventilation-perfusion 
scan, only a few, i.e. approximately 2%, of the patients will be identified. Hence, it 
seems to be more feasible to use the current decision rule as a cheap and simple 
test for the exclusion of pulmonary embolism. This appears to be possible in 16% 
(22 out of 137) of the patients. 
The clinical decision rule is easily applicable in the form presented here. 
Imagine a patient with chronic obstructive pulmonary disease, without a prior 
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history of deep venous thrombosis, who presents with fever, a recently worsened 
cough, wheezing and pain related to breathing which instigates the suspicion of 
pulmonary embolism. A perfusion scan is made which shows multiple defects, and 
the ventilation-perfusion scan has a non-high probability result. The clinical 
decision rule is subsequently applied to see whether pulmonary embolism can be 
ruled out. This patient will have a score of -3.068 (wheezing present) + 0.9554 
(recently worsened cough) + 0.8847 (body temperature above 37°C) + 0.9828 
(multiple defects on perfusion scan) - 2.455 (constant) = -2.7001, which is below 
the optimal cut-off point of -2.512 for the exclusion of pulmonary embolism. In this 
patient the presence of pulmonary embolism is made un likely by the clinical 
decision rUle. If the patient would have had a previous history of deep venous 
thrombosis the score would change to -0.8141, which is above the cut-off point. For 
that patient the clinical decision rule can not help in the exclusion of pulmonary 
embolism and other diagnostic tests are necessary. 
Several aspects of the present investigation warrant comment. The first issue 
is that the rule was based on data of only 137 patients. In constructing the rule we 
preferred to base it on data from the patient population in which it will be used, 
rather than include data on patients with a normal or a high probability ventilation-
perfusion scan result. Since the number of variables included in the rule is small, 
relative to the number of patients, it seems unlikely that over-modelling took place. 
Furthermore, although the number of patients was limited, they were consecutive 
and the study was controlled by angiography. 
Secondly, some clinical symptoms and signs that are frequently cited in 
textbooks to be associated with pulmonary embolism were not included in the 
model. In presenting such criteria, textbooks may be focusing on the total patient 
population presenting with symptoms of pulmonary embolism, rather than on 
specific sub-populations, such as those with non-diagnostic lung scan findings. 
Table 1 shows that many of these criteria do not discriminate between patients with 
and without pulmonary embolism in an univariate analysis in the patient population 
studied here. Forcing the well-known criteria into the multivariate regression 
analysis did not improve the model. 
The third issue is that several variables had to be discarded in the process of 
constructing the rule. Whereas some variables, such as arterial blood gas, heart 
failure and abnormal heart sounds, may seem feasible beforehand, their definition 
or reproducibility is cumbersome, causing many missing values or inconsistent 
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data. The decision rule presented here is based on variables that proved to be 
collectable in the acute clinical setting of a large teaching hospital, whereas other 
decision rules frequently contain items that are difficult to reproduce in practice8 •9 
The last issue is that the clinical decision rule may lose predictive value if the 
patient population changes. Whereas this may certainly be true for large changes 
in e.g. the prior probability of pulmonary embolism, the results of the 
microsimulation in the 1000 random sub-sets of patients point to a reasonable 
robustness of the combination of variables in sub-populations of the patient 
population studied. 
The current study presents the results of the derivation of a clinical decision 
rule. The next step should be validation of this rule in a large prospective trial, since 
earlier studies revealed that the predictive value may decrease significantly upon 
re-evaluation. Other items for future study could be whether clinical decision rules 
can add information to the result of other non-invasive tests such as compression 
ultrasonography or a D-dimer blood test. 
We showed that it is possible to derive a simple quantitative clinical decision 
rule for patients with a non-high probability result of the ventilation-perfusion scan, 
and that its major application probably lies in ruling out pulmonary embolism. 
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Chapter 3. Preparatory phase: selection of strategies 
THE COST-EFFECTIVENESS OF DIAGNOSTIC STRATEGIES IN 
PATIENTS WITH SUSPECTED PULMONARY EMBOLISM' 
Summary 
The cost-effectiveness of various diagnostic strategies in patients with 
clinically suspected pulmonary embolism (PE) was analysed using a modelling 
approach. In 451 consecutive patients with clinically suspected PE data on the 
performance of diagnostic tests were collected prospectively in two large teaching 
hospitals in Amsterdam, the Netherlands. The ventilation-perfusion lung scan was 
used as the primary diagnostic test in all patients. In patients with a non-diagnostic 
lung scan result the performance of a clinical decision rule, a D-dimer test, and 
ultrasonography of the leg veins was evaluated with pulmonary angiography as the 
gold standard. It was estimated that the strategy recommended by a 1992 Dutch 
consensus meeting costs about DFL 4,400 per patient and that 97.02% of the 
patients can be expected to survive the first six months after the primary PE. The 
nation-wide annual costs for the diagnosis and treatment of patients by this 
strategy were estimated at 163 million Dutch GUilders. Subsequently, the costs and 
effects of alternative strategies were evaluated in a modelling approach, and 
compared to those of the consensus strategy. One strategy was selected that 
produces the best results in terms of survival and leads to considerable savings as 
compared to the consensus strategy. In this strategy subsequently a ventilation-
perfusion scan, a clinical decision rule, a D-dlmer test, a pulmonary angiography 
and leg ultrasonography are performed. Patients with a high probability ventilation-
perfusion scan, an abnormal angiography or leg ultrasound test are treated, 
whereas treatment is withheld in patients with a normal ventilation-perfusion scan, 
a normal clinical decision rule, a negative D-dimer test, a normal angiography, or a 
normal leg ultrasound test. This strategy will have to prove its value and usefulness 
in clinical practice in a subsequent prospective validation phase . 
• Based on: Michel BC, Seerden RJ, Beek EJR van, BOiler HR, Rutten FFH. The cost-effectiveness of 
diagnostic strategies in patients with suspected pUlmonary embolism. SUbmitted. 
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Introduction 
Pulmonary embolism (PE) is a serious and potentially life-threatening 
disease. Together with deep leg vein thrombosis it is regarded as part of the 
clinical entity venous thromboembolism. The current view-point is that PE is a 
complication of deep leg vein thrombosis, in which parts of the thrombosis 
embolise to the systemic circulation and cause complete or partial obstruction of 
the pulmonary arterial blood flow to the lung. Large emboli may cause immediate 
death, small emboli may pass unnoticed. If patients surviving the initial PE remain 
untreated, between 18 and 26 percent may die of recurrent embolism.
,
,2 The 
current treatment policy aims at preventing recurrent embolism, and generally 
consists of intravenous heparin, followed by three to six months oral anticoagulant 
therapy. Unfortunately, these preventive treatments may have serious side-effects, 
most notably fatal haemorrhage."" Thus, immediate initiation of an appropriate 
diagnostic strategy is called for, as soon as the diagnosis PE is clinically 
suspected. Whereas general treatment policies may depend on the incidence of 
PE in the patient population, for every individual patient suspected of having PE a 
trade-off between the risks of recurrent embolism and the risks of anticoagulant 
therapy must be made. For this decision an accurate diagnosis of the presence or 
absence of PE is warranted. 
Diagnosing PE is a challenging problem. Signs and symptoms, like shortness 
of breath, pain related to breathing, fever, bloody sputum and palpitations, are non-
specific and may occur in many other diseases. In most patients the history and 
physical examination will not be sufficient to diagnose or exclude PE: additional 
diagnostic tests will be required. For this purpose a perfusion lung scintigraphy is a 
relatively safe initial diagnostic tool that is widely available." A normal scan 
effectively rules out PE, but an abnormal scan does not sufficiently prove the 
diagnosis. In patients with an abnormal perfusion scan a ventilation lung scan 
usually is the next step in the diagnostic strategy·'· If the combined ventilation-
perfusion scan shows at least a segmental perfusion defect with normal ventilation, 
the scan is designated "high probability", which is generally believed to confirm the 
disease. But, unfortunately, in apprOXimately 40% to 50% of the patients the result 
of the ventilation-perfusion scan is inconclusive: a "non-high probability" or non-
diagnostic result. In these patients additional diagnostic tests are necessary to 
prove or exclude PE. 
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A 1992 consensus meeting of Dutch pulmonologists and internists 
recommended a policy of ventilation-perfusion scanning, followed by 
ultrasonography of the deep leg veins in case of an inconclusive ventilation-
perfusion scan and a pulmonary angiography in case of a normal leg ultrasound as 
the most appropriate diagnostic strategy in PE, figure 1.9 This strategy corresponds 
with recommendations made by authors from other countries.'o", 
Figure 1 The slralegy recommended by Ihe Dulch consensus meeting in 1992, which 
was used as Ihe basis for IlIis sludy. VQscan = venlilalion perfusion scan; NH 
= non-high probabilily; US = ultrasound 
abnormal 
• treatment 
abnormal treatment 
abnormal .... 
• 
treatment 
normal NH angiography 
VQscan US 
normal 
no treatment 
normal 
no treatment 
However, pulmonary angiography - which is seen as the gold standard for the 
presence or absence of PE - is not always available, requires expertise, and may 
lead to serious, sometimes even lethal, complications.'2 Therefore, other 
strategies, including non-invasive tests such as a D-dimer test (a simple blood test 
aimed at confirming the existence of degradation products from the thrombus) or a 
clinical decision rule, are continuously being searched for. 13.'8 
The object of the current study is to assess the costs and effects of the Dutch 
consensus strategy and to compare these with the costs and effects of alternative, 
possibly less invasive, strategies. 
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Patients and methods 
In a prospective study data on the sensitivity and specificity of various 
diagnostic tests, the costs of diagnostic tests and treatment, the costs and 
occurrence of complications, and the occurrence and cause of death were 
collected. Subsequently a model was built combining these data in order to 
evaluate and compare the costs and effects of diagnostic strategies in patients with 
clinically suspected PE. 
PATIENTS 
Between June 1991 and April 1994 all patients (487) seen with suspected PE 
in two large teaching hospitals in Amsterdam, the Netherlands, were included in a 
prospective cohort study. Written informed consent was obtained from all patients 
and the study was approved by the Institutional Review Boards of both hospitals. 
All patients were scheduled for lung scintigraphy. If the lung scan was "high 
probability" anticoagulant treatment was initiated (or continued), whereas treatment 
was withheld if a normal lung scan was obtained.8 In patients with a "non-high 
probability" lung scan result, leg ultrasonography (aimed at confirming the 
presence of deep leg vein thrombosis), pulmonary angiography and several 
plasma D-dimer tests were performed. In the present analysis only the most 
informative D-dimer assay (Diagnostica Stago, Asniere, France) was used.'· 
Additionally, at the time of inclusion into the study, clinical data were recorded 
by the attending physician for the construction of a clinical decision rule. The rule 
that was made with these data contains previous deep venous thrombosis, a 
recently developed or worsened cough, body temperature above 37°C, multiple 
defects on the perfusion scan and the absence of wheezing as predicting 
variables. Details on the use and construction of this rule are described in chapter 
2. 
In all patients, data were recorded on the number of hospital days, the 
diagnostic tests that were performed and their results, the number of days of 
heparin treatment, the presence of co-morbidity, the number of days of oral 
anticoagulant therapy, and the occurrence of bleeding complications and recurrent 
PE during the initial hospitalisation and the 6 months follow-up period. Finally, the 
date and probable cause of death were registered. 
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COSTS 
The costs of the diagnostic strategies were made up of two components: the 
volume of medical activities (average number of hospital days per patient, 
diagnostic tests, days of heparin treatment, etc.) multiplied by their monetary 
valuation. Thus, only direct costs made within the health care sector were 
calculated, whereas costs made by the patients and indirect costs, such as 
production losses, were not taken into account. All costs were calculated in Dutch 
Guilders (1 DFL = £ 0.40; 1 DFL = $ 0.64; conversion rates October 1995) 
Detailed price calculations were performed in the Academic Medical Centre in 
Amsterdam, the Netherlands, to estimate unit costs reflecting the real use of 
resources. These calculations included the costs of manpower, materials, 
equipment and overheads. The costs of manpower were based on the medium 
salaries in the gross salary scales for Dutch University Hospitals, and included a 
35% increase for social security premiums. Costs of equipment concerned 
depreciation, interest and costs of maintenance. The first two were calculated on 
the basis of an economical lifetime of 8 years and an interest of 5%, whereas the 
yearly costs of maintenance were based on expert opinion and estimated at 8% of 
the initial expense. 
Costs for hospital days were separated from costs for treatment and costs for 
diagnostic tests and based on the hospital cost accounting system of 1992. They 
were calculated as the weighted average costs for a hospital day in the relevant 
wards in the Academic Medical Centre, including costs of salaries for medical 
specialists and overheads. 
For the costs of treatment with heparin on the medical ward only the costs of 
standard laboratory tests and the heparin pump were included. The other 
components were already included in the costs for hospital days. 
The calculation of the costs for treatment wilh oral anticoagulants was based 
on data collected from Dutch Thrombosis Services, which are specialised in 
outpatient anticoagulant treatment. These costs included two consultations per 
patient per month and an average of 3 tablets of acenocoumarol 1 milligram daily. 
As length of treatment wilh oral anticoagulants the average duration of treatment of 
the patients in the study, with a maximum of 6 months per patient, was included. 
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Because at least 73% of the patients in the study had some form of, 
sometimes serious, co-morbidity the length of stay (LOS) in hospital for the 
diagnosis and treatment of PE had to be separated from the LOS for the co-
morbidity. In determining the average LOS for PE, only hospital days that were 
necessary for the diagnosis of PE and treatment with intravenous heparin were 
included. If the real LOS was less than three days longer than necessary for 
diagnosis of PE and treatment with intravenous heparin, it was assumed that these 
days were necessary for practical purposes related to the pulmonary embolism, 
and therefore all these days were ascribed to the PE. If the real LOS was more 
than 3 days longer, only days necessary for diagnosis of PE and treatment with 
intravenous heparin were ascribed to the PE, and it was assumed that the other 
days were related to the patient's co-morbidity. 
The average costs of a bleeding complication were estimated by multiplying 
the length of stay in hospital for each complication with the average cost of a 
hospital day and adding charges for standard procedures, depending on the site of 
the bleeding. For cerebrovascular bleeding average real costs were used, based 
on a previous study (unpublished data). The average costs of diagnosing and 
treating recurrent clinical PE were estimated by multiplying the length of stay in 
hospital with the average costs of a hospital day and adding the average costs of 
diagnostic and therapeutic interventions of a primary PE. The average costs of a 
hospital day for complications were estimated to be identical to the average costs 
of a hospital day for a primary PE. 
EFFECTS 
Effects were calculated as the 6 month survival probability. Complications of 
treatment, mainly bleedings, and re-occurrence of PE were based on their 
occurrence in the study patients. Minor complications that would not lead to 
additional diagnostic or therapeutic procedures or hospital days, e.g. a small 
haematoma, were not taken into account. Mortality of the angiography was based 
on literature and estimated at 0.2%.12.19 
THE MODEL 
The model was based on the observed sensitivity and specificity of the 
separate diagnostic tests in the patients who participated in the study, with the 
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angiography as the gold standard. Furthermore, data on the incidence of PE in the 
patient population and the occurrence of PE-related deaths and major 
complications were included. The model was a decision tree constructed in a 
spreadsheet programme (Quattro Pro for Windows, version 5.0, Borland 
International, Inc, 1993) to enable full flexibility. Bayes' theorem was used to 
calculate the joined sensitivity and specificity for combinations of tests, assuming 
independence of the various diagnostic tests. In the model diagnostic strategies 
were applied to 100 imaginary patients. For each diagnostic strategy all possible 
combinations of test results were defined, and the number of patients with each 
combination of test results and the probability of their having PE were calculated. 
Then the costs for tests, treatment and complications, and the survival of patients, 
based on the mortality of treatment (if given) and the mortality of recurrent PE, 
were calculated for each combination. And finally the average costs and survival 
for the diagnostic strategy were calculated by summing the sub-totals for all 
combinations and dividing the thus obtained results by 100. This process was 
repeated to calculate the costs and effects of all possible diagnostic strategies. 
Both the clinical decision rule and the D-dimer test had variable sensitivity 
and specificity depending on the cut-off points that were chosen. For the D-dimer 
nine cut-off points, at every 100 mgll between 100 mg/I and 900 mg/I, were 
included in the analysis. For the clinical decision rule all sixteen cut-off points at 
which the sensitivity and/or specificity of the rule changed were included in the 
analysis. 
Strategies in which the clinical decision rule or the D-dimer test were 
scheduled to be performed in case the angiography was unavailable or 
inconclusive were not included in the final analysis, because the sensitivity and 
specificity of the tests performed in this specific sub-population of patients were 
thought to be unreliable. All other scenarios were arranged according to the 
expected gain in survival and the additional costs relative to the Dutch 1992 
consensus strategy: Scenarios which were dominated by scenarios involving less 
costs with an equal or belter survival probability, were omitted from the final 
evaluation. For each of the remaining "dominant" strategies a gain in survival can 
be attained at certain costs in comparison with the previous strategy. The ratio 
between the additional costs and the additional effects of a strategy relative to the 
previous strategy was called the incremental cost-effectiveness ratio (incremental 
CE-ratio). 
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The variables used in the calculations of the costs and effects of the various 
strategies are surrounded by uncertainty margins. The effects of these 
uncertainties in the final outcome were evaluated in a sensitivity analysis. 
Results 
A total of 487 consecutive patients were included in the clinical study. For 36 
patients no data were available for the cost-effectiveness analysis. Table 1 
presents the baseline clinical and sociodemographic characteristics of the 
remaining 451 patients. 
Table 1 The baseline clinical and sociodemographic characteristics of the 451 
patients included in the cost-effectiveness analysis 
Age; average (SD) 
Male/female 
Co-morbidity (%) 
-Chronic Obstructive Pulmonary Disease 
-Malignancy 
Patients referred by the emergency department (%) 
Risk factors for pulmonary embolism (%) 
-Recent surgery 
-History of venous thrombo-embolism 
Signs of deep leg vein thrombosis (%) 
Days of symptoms; average (SD) 
, 446 patients; b 450 patients; C 449 patients; d 443 patients 
56.4 (17.6)' 
193/258 
93 (20.6%) 
103 (22.8%) 
266 (59.0%) 
95 (21.1%) 
33 (7.3%)b 
39 (8.7%)C 
7.2 (14.7)d 
On average two hospital days were necessary for diagnosing or excluding PE 
in these patients. Four-hundred-and-forty-four of these patients had a ventilation-
perfusion scan, 126 (28%) with a normal result and 132 (30%) with a high 
probability result. In the remaining 186 (42%) patients the result of the ventilation-
perfusion scan was inconclusive. 
In 40 of the 186 patients with a "non-high probability" result of the ventilation-
perfusion scan angiography could not be performed for various technical reasons, 
and in 6 additional patients the angiogram could not be interpreted. In the 
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remaining 140 patients 38 patients had an abnormal angiogram, hence the 
prevalence of PE in patients wilh a "non-high probability" lung scan was 27%. 
Table 2 gives an overview of the sensitivity and specificity of the various tests, 
wilh the pulmonary angiography as the gold standard. 
, 
b 
, 
d 
Table 2 Sensitivity, specificity and 95% confidence intelYal (el) for the ventilation-
perfusion scan, the leg ultrasound and several cut-off points ("cut-offJ for the 0-
dimer test and the clinical decision rule 
Test cut-off sensitivity (CI) specificity (CI) 
Ventilation'perfusion scan' 0.68 (0.61-0.75) 0.44 (0.38-0.50) 
Deep leg vein ultrasonography' 0.29 (0.12-0.45) 0.96 (0.90-0.99) 
D-dimerc 300 1.00 (0.90-1.00) 0.12 (0.03-0.20) 
500 0.89 (0.72-0.98) 0.29 (0.18-0.41) 
700 0.75 (0.57-0.93) 0.44 (0.32-0.57) 
Clinical Decision Rule' 0.075 1.00 (0.91-1.00) 0.22 (0.13-0.30) 
0.192 0.78 (0.63-0.93) 0.67 (0.58-0.77) 
0.358 0.44 (0.27-0.62) 0.83 (0.75-0.91) 
0.592 0.11 (0.00-0.23) 1.00 (0.97-1.00) 
In 444 patients with a ventilation-perfusion scan. The prevalence of PE in high 
probability (88%) and negative scans (4%) is based on data from literature' It is 
assumed that the prevalence of PE in the 46 patients with a non-high probability scan, 
but without an interpretable angiography, is identical to the prevalence in the 140 
patients wllh an interpretable angiography (27%). 
In 131 patients with a non-high probability ventilation-perfusion scan, a leg ultrasound 
and an interpretable angiography 
In 96 patients with a non-high probability ventilation-perfusion scan, a Stago D-dimer 
test and an interpretable angiography 
In 137 patients with a non-high probability ventilation-perfusion scan, an interpretable 
angiography and sufficient clinical data to complete the clinical decision rule 
Treatment with oral anticoagulants was given for 3.7 months on average. The 
average duration of treatment with heparin was 5.4 days. Two of the 38 patients 
who were treated with anticoagulant therapy after an abnormal angiogram 
subsequently had a lethal recurrent PE within 6 months (5.3%). The number of 
clinical recurrences, warranting hospital admission and additional diagnosis and 
thereby causing additional costs, was 2.6 times the number of lethal recurrences. 
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One patient died due to a fatal haemorrhage during heparin treatment, while 
heparin was used for a total of 1806 patient days. Nine patients had a major 
bleeding episode during a total of 709 patient months of oral anticoagulant 
treatment, one of these patients died. Table 3 gives an overview of the costs per 
unit, which were used in the calculations. 
Table 3 Costs (in Dutch Guilders) per unit as included in the model. 
Item 
Hospital day 
Treatment wilh heparin: 1 sl day 
following days 
Trealment with acenocoumarol per monlh 
D-dimer test 
Leg ultrasound 
Clinical decision rule 
Pulmonary angiography 
Perfusionscan 
Ventilation-perfusion scan 
Bleeding complicalion 
Recurrent pulmonary embolism 
Costs 
DFL 568.00 
DFL 26.83 
DFL 13.23 
DFL 42.33 
DFL 43.00 
DFL 68.00 
DFL 40.00 
DFL 765.00 
DFL 313.00 
DFL 549.00 
DFL 6,601.56 
DFL 4,014.00 
The model showed that diagnosing (or excluding) PE with the consensus 
strategy costs approximately DFL 4,398.23 per patient and that 97.02% of the 
patients can be expected to survive the first 6 months after the primary PE. These 
results were compared with the costs and effects of 11,605 alternative scenarios. 
Subsequently 11,563 scenarios that were dominated by better ones were omitted. 
In 12 of the remaining 42 "dominant" strategies less investment than in the 
consensus strategy yielded more survival. 
Table 4 gives an overview of the costs and effects of these 12 strategies. For 
these 12 strategies the incremental CE-ratio relative to the previous strategy is 
presented in a separate column. In this overview a large incremental CE-ratio 
means that large investments will have to be made to gain additional survivors 
relative to the previous strategy. It will not be efficient to choose a strategy with a 
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high incremental CE-ratio relative to the previous strategy (like strategy 4). Neither 
will it be efficient to use a strategy that is followed by a low incremental CE-ratio 
(tike strategy 7). Figure 2 shows the non-decreasing function of survival relative to 
costs for the dominant strategies relative to the consensus strategy. The strategies 
on top of the small notches of the line are the most appealing strategies, like 
strategies 3, 8 and 12. These strategies combine relatively low costs with a high 
survival in comparison with the neighbouring strategies. 
Figure 2 The non-decreasing function of survival relative 10 cosls for Ihe 12 dominanl 
slralegies, compared 10 Ihe consensus slralegy. The numbers near the line 
indicale Ihe number thai was given to Ihe slrategy in table 4. 
12 0.004 
13 
11 0.003 
0.002 
3 4 
0.001 
2 
r.i~-------r----------r---------40 
-300 -200 -100 o 
Additional costs 
The last column of table 4 shows the nation-wide costs of diagnosing and 
treating 37,000 patients annually for each of the diagnostic strategies?O The 
nation-wide costs of diagnosing and treating PE range from 75 (for a strategy in 
which no tests are performed and no treatment is provided) to 163 million Dutch 
Guilders per year. 
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Table 4 Average costs and effects per patient and nation-wide costs of the 12 "dominant" strategies in patients with a non-high 
probability ventilation-perfusion scan, which yield a better survival than the consensus strategy. us = ultrasound; angio = 
angiogram; ddimer400 = D-dimer test with cut-off pOint 400; cdrO.192 = clinical decision rule with cut-off point 0.192; (-) = if 
result is negative; (+) = if result is positive; (np.in) = if not possible or inconclusive; pp = per patient. 
Strategy costs pp 6 months additional additional incremental national 
survival costs survival CE-ratio costs 
Reference: us(-)angio(np.in)treatment 4,398 0.9702 162,734,510 
2 cdrO.192(+)ddimer400(+)angio(np.in)us 4,118 0.9705 -280 0.0003 23,925 152,374,880 
3 cdrO.192(+)ddimer300(+)angio(np.in)us 4,150 0.9712 -248 0.0010 45,243 153,546,670 
4 cdrO.175( + )ddimer400( + )angio( np. in)us 4,195 0.9713 -204 0.0011 446,200 155,197,610 
5 cdrO.125( + )ddimer500( + )angio(np. in jus 4,217 0.9716 -181 0.0014 75,900 156,040,100 
6 cdrO.092(+)ddimer500(+)angio(np.in)us 4,221 0.9717 -177 0.0015 37,200 156,177,740 
7 cdrO.175(+)ddimer100(+)angio(np.in)us 4,229 0.9719 -169 0.0017 39,200 156,467,820 
8 ddimerBOO(+)cdrO.075(+)angio(np.in)us 4,234 0.9723 -164 0.0021 13,125 156,662,070 
9 ddimer500(+)cdrO.075(+)angio(np.in)us 4,262 0.9727 -136 0,0025 69,775 157,694,740 
10 ddimer400(+)cdrO.025(+)angio(np.in)us 4,276 0,9730 -123 0.0028 45,100 158,195,350 
11 ddimer400 (+ )cdrO .075 (+ )angio( np.in)us 4,288 0.9733 -110 0.0031 42,833 158,668,580 
12 cdrO.042(+)ddimer300(+)angio(np.in)us 4,314 0.9740 -84 0.0038 37,214 159,632,430 
13 cdrO.075(+)ddimer300(+)angio(np.in)us 4,339 0.9742 -59 0.0040 124,000 160,550,030 
Preparatory phase: selection of strategies 
Table 5 provides an overview of the results of a sensitivity analysis in relation 
to the strategy with the highest survival (strategy 13). This shows that the number 
of hospital days has a major influence on the costs. The percentage of treated 
patients dying of recurrent PE has an important influence on the estimated survival. 
If this percentage increases from 5.3%, in the baseline scenario, to 6.3%, survival 
decreases by 0.4%. The percentage of untreated patients dying of recurrent PE 
turned out to have a smaller impact on survival. 
Table 5 Resul/s of Ihe sensitivity analysis for some of Ihe main variables in Ihe model. 
(BL: ) ~ value of item in basetine scenario 
Baseline scenario 
Lethality untreated PE 26% (BL: 18%) 
Lethality untreated PE 38% 
Lethality recurrent PE treated 6.4% (BL: 5.3%) 
Costs bleeding complications DFL 5,600 (BL: DFL 6,602) 
Costs bleeding complications DFL 7,600 
Costs recurrent PE DFL 3,000 (BL: DFL 4,014) 
Costs recurrent PE DFL 5,000 
Three hospital days necessary for diagnosis (BL: 2) 
1 bleeding complication J 100 patient years of treatment (BL: 1.7) 
4 bleeding complications J 100 patient years 
7 bleeding complications 1100 patient years 
costs in 6 months 
DFL survival 
4,339 97.42% 
4,349 97.33% 
4,364 97.18% 
4,377 97.05% 
4,321 97.42% 
4,358 97.42% 
4,285 97.42% 
4,392 97.42% 
4,916 97.42% 
4,289 97.51% 
4,507 97.14% 
4,724 96.78% 
Another major influence on survival is seen in the number of bleedings in 100 
patient years of treatment with oral anticoagulants. In this paper the definition of 
bleeding (any bleeding likely to cause extra costs) was broader than the definition 
"major bleeding" in a large Dutch study into the complications of anticoagulant 
treatment:' The total number of bleeding episodes (15.3 per 100 patient years) in 
our study was smaller than in patients receiving oral anticoagulants because of 
non-arterial disease in the above mentioned study (21.1 per 100 patient years), but 
much larger than the number of major bleedings in that study (3.9 per 100 patient 
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years). The number of falal bleedings was in the same order of magnitude (1.7 per 
100 patient years in our study vs. 1.2). Even though table 5 shows that the 
frequency of bleeding has a major influence both on costs and survival, sensitivity 
analysis shows that the ordering of the 12 strategies will remain unchanged if an 
increase in fatal bleedings to 7 per 100 patient years occurs in combination with an 
increase in (both fatal and non-fatal) bleedings to 63 per 100 patient years, or if a 
decrease in fatal bleedings to 1 per 100 patient years occurs in combination with a 
decrease in total bleedings to 9 per 100 patient years. 
The effects of the confidence intervals surrounding the sensitivity and 
specificity on the costs and effects for the dominant strategies are presented in 
figure 3. This figure shows that for the leg ultrasound changes in sensitivity and 
specificity within the confidence intervals had little influence on the ordering of the 
12 dominant strategies. 
Here only the influence of the confidence intervals surrounding the sensitivity 
and specificity of the leg ultrasound are presented. For the other diagnostic tests 
sensitivity analysis was thought to be less opportune. The ventilation-perfusion 
scan was used in all patients as the first test, therefore a change in sensitivity or 
specificity of this test would not influence the ordering of the strategies. For the D-
dimer and clinical decision rule many values for sensitivity and specificity were 
already included in the baseline analysis. And the angiography was used as the 
gold standard with perfect test results. 
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Figure 3 Resulls of the sensitivity analysis for changes in the sensitivity (sens) and 
specificity (spec) within the confidence intervals for the leg ullrasound 
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DISCUSSION 
At present, the evaluation of costs and effects plays a major role in the 
decision about the distribution of health care services. Whereas the major focus is 
on the cost-effectiveness of therapeutic technologies, large sums of money are 
spent on the diagnosis of diseases with a high incidence in the general population. 
The current analysis shows that under the Dutch consensus strategy approximately 
DFL 163 million is spent on the diagnosis and therapy of PE annually, amounting to 
0.4% of the total costs of health care in the Netherlands in 1988. This is 
considerably more than the total costs spent on the diagnosis and treatment of 
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prostate cancer (110 million) or stomach cancer (99 million) in 1988 in the 
Netherlands.22 
Here, a modelling approach towards the analysis of the cost-effectiveness of 
diagnostic strategies in pulmonary embolism was chosen to select the most 
favourable diagnostic strategy from a large variety of possible strategies. Because 
the selected 12 strategies all show both savings and longer survival compared to 
the baseline strategy, the incremental cost-effectiveness when considering one 
strategy after another helps to select the most efficient strategy. More specifically, 
a strategy is relatively efficient when the incremental cost-effectiveness relative to 
the previous strategy is low and the incremental cost-effectiveness of proceeding to 
the next strategy is high. 
In order to place the current results in perspective we made a rough 
calculation of the costs per QAL Y for each strategy. Survival was converted to 
QAL Ys by calculating the average life expectancy for the patients in the study, 
according to their age and sex with data from the Dutch Central Bureau for 
Statistics. Because of considerable co-morbidity in the patient population we 
reduced the life expectancy by an arbitrary 25%. The average quality of life of 
patients was set at the descriptive scores of the EuroQol questionnaire three 
months after the PEn These scores were transformed to a normalised 0 to 1 scale 
using median values of the Dutch general public:' The correction factor for quality 
of life of 0.7 that was thus obtained, was assumed to remain constant over the rest 
of the patients' life. After discounting by 5%, an average life expectancy of 9.2 
QAL Ys was estimated. This estimation was subsequently used to convert the 
incremental CE-ratios into incremental costs per QAL Y. Under these assumptions 
the maximum incremental CE-ratio equals DFL 48,365 per QAL Y (strategy 3 to 
strategy 4). This does not surpass the ratio of DFL 55,000 per QAL Y, that was 
deemed acceptable when deciding to introduce liver transplantation and heart 
transplantation in the Netherlands. However, it should be noted that for less path-
breaking technologies the threshold may be lower than DFL 55,000 per QAL Y. If 
an incremental CE-ratio of less than DFL 55,000 per QAL Y is accepted as cost-
effective, the strategy with the maximum survival (strategy 13) will be the preferred 
choice. (Table 4) The CE-ratio of this strategy relative to the consensus strategy, 
can be estimated at minus DFL 1,600 per QAL Y. 
In strategy 13 subsequently a ventilation-perfusion scan, a clinical decision 
rule, a D-dimer test, a pulmonary angiography and leg ultrasonography are 
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performed. Patients with a high probability ventilation-perfusion scan, an abnormal 
angiography or an abnormal leg ultrasound test are treated with anticoagulants, 
whereas treatment is withheld in patients with a normal ventilation-perfusion scan, 
a normal clinical decision rule, a negative D-dimer test, a normal angiography, or a 
normal leg ultrasound test. Figure 4 gives an overview of the numbers of patients 
with normal or abnormal test results, according to the model, for strategy 13. This 
strategy combines the various available diagnostic methods in a clinically useful 
way by performing simple non-invasive tests first (such as the ventilation-perfusion 
scan, the clinical decision rule and the D-dimer test). Hence, pulmonary 
angiography, a method which requires cardiac catheterisation, is limited to patients 
with non-diagnostic non-invasive test results. 
Figure 4 The diagnostic strategy that produces the best results in terms of sUlYival in 
combination with considerable savings relative to the consensus strategy. 
VQ-scan = ventifation-perfusion scan, CDR = ctinical decision rule, US = 
ultrasonography, angio = angiography, + = abnormal test result, - = normal 
test result, NH = non-high probability result. The numbers are the numbers of 
patients with the specified combination of test results, predicted by the model 
for an imaginary 100 patients. 
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In estimating costs of diagnosis and treatment of PE, co-morbidity plays a 
major role. In the patient population analysed 73% of the patients had some form 
of concurrent disease, implying that all costs for PE had to be separated from the 
costs made for the concurrent disease. In this analysis, the arbitrary decision was 
made to attribute all hospital days to PE in which diagnostic or therapeutic 
procedures for PE were performed. These costs are overestimated if patients had 
to stay in hospital anyway because of their co-morbidity. 
Another major assumption in the current analysis was that of the 
independency of the tests. We felt that this assumption was justified because the 
tests included in the analysis all had their impact at different points of the 
thrombosis forming process. The effect of this assumption and of missing values 
for the separate tests was analysed by applying strategy 13 to the original 
database. No important differences were observed. The model predicted that 
31.7% of the patients would need pulmonary angiography for an accurate 
diagnosis, whereas application of the strategy to the original database showed that 
32.1 % of the patients would have to undergo this test. With the model it was 
predicted that 6.6% and 2.8% of the patients would not have to be treated because 
of a negative clinical decision rule or a normal D-dimer test. In reality this was the 
case in 7.5% and 1.5% of the patients, respectively. 
Despite the fact that large sums are spent on the diagnosis and treatment of 
PE, mainly because of its high incidence, to our knowledge only one previous study 
on the costs and effects of PE was performed. That study by Oudkerk et al was not 
based on (prospective) patient data and did not include detailed cost calculations 
nor quality of life data." The study resulted in a recommendation to apply the 
consensus strategy as the most cost-effective strategy. The current analysis shows 
that the addition of non invasive tests may improve considerably on this strategy. 
The next step will be to validate the most favourable strategy in a prospective 
study in a clinical setting. Especially the sensitivity and specificity of the clinical 
decision rule requires further validation. 
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Chapter 4A. Substitution control group: method 
ASSESSING THE BENEFITS OF TRANSPLANT SERVICES' 
Summary 
This chapter presents some methods for the assessment of transplant 
benefit?, including modelling techniques. An independent assessment of the 
benefits of medical technology is especially important for the evaluation of the 
balance between the costs and benefits involved. To enable comparison with other 
health-care facilities, benefits are defined in terms of a combination of life-years 
gained and quality of life. The number of life-years gained can be calculated by 
comparing the survival expected with and without transplantation. Survival with 
transplantation is estimated on the basis of observed survival, acknowledging that 
the probability of survival may have changed over time, owing to changes in 
therapy and selection criteria. To estimate survival without transplantation, several 
techniques are available. Prognostic models, correcting for stage of disease, are 
often used. Pitfalls in the use of these models are discussed_ The number of life-
years gained can be corrected for quality of life, by weighing survival with and 
without transplantation with an index representing quality of life. A method for the 
calculation of such an index is given. A practical application of the methods 
described here will be presented in chapter 48. 
Introduction 
Nowadays transplant services are provided all over the world for patients with 
end-stage heart, liver or renal failure. Ideally, new medical technologies develop 
from an experimental to a non-experimenlal status in steps that are marked by the 
results of phase II and III clinical trials. While phase II trials concentrate on activity 
and safety and try to identify the best treatment protocol in small numbers of 
• Based on: Michel BC, Hout BA van, Bonsel GJ. Assessing the benefits of transplant services. BaiHiere's 
Clinical Gastroenterology 1994; 8(3): 411·423. Copyright © 1994, by Bailliere Tindall. 
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patients,1 phase III trials assess the overall benefits of the technology following a 
fixed protocol and are organised in such a way that statistical evaluation is 
possible. 
Heart, liver and renal transplantation are no longer considered experimental, 
although their development towards this status has not been characterised by the 
above mentioned steps. However, some parallels can be observed. After the first, 
disappointing, results in the 1960s, both surgeons and physicians gained 
experience in the selection and investigation of patients, the timing of surgery in the 
course of disease, surgical and ana esthetical techniques, postoperative care and 
the detection and treatment of rejection. New and better immunosuppressive 
agents were sought and found: and one might call this stage - which lasted for 
about 20 years - the equivalent of a phase II trial. A similar equivalent of the 
randomised controlled phase III trial cannot be found. When in the early 1980s the 
first favourable post-transplant survival curves were published,3,4 transplantation 
rapidly became an established form of therapy. While the number of transplant 
centres increased steadily, no formal experimental comparison was ever carried 
out. The obvious reason for this is that, because transplant services showed more 
and more favourable effects, randomised controlled trials comparing 
transplantation with alternative strategies rapidly became unethical.5-7 So, 
assessment of the benefits has to be based on other types of information. 
If safety and efficacy are proven, and if effects are favourable in comparison 
to those of alternative strategies, what is the relevance of a precise assessment of 
benefits? The answer is costs. New medical technologies often cause health-care 
budgets to increase and in most Western countries it is common practice to 
question whether the additional benefits are worth the additional costs. The 
concept of "value for money" has been introduced in health care, most notably in 
the market for pharmaceuticals,' but also for other health-care interventions."·1o 
Economic evaluation is acknowledged as the appropriate technique to assess the 
balance between additional costs and additional benefits. In most circumstances 
the outcome of such studies is summarised in terms of a so-called cost-
effectiveness ratio: additional costs in the numerator and additional benefits (in 
terms of improvement in health status) in the denominator. However, the demand 
for cost-effectiveness information has various implications. First, to be able to 
calculate such a ratio, the knowledge that a therapy has positive effects is not 
enough; rather, a precise estimate of the effects should be available. Second, a 
common summary measure of benefits is asked for, that is relevant across all kind 
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of health-care facilities. As a consequence, it is now common practice to try to 
express the benefits of a medical technology in terms of "quality-adjusted-life-years 
gained", combining life-years gained with an index representing the value of quality 
of life." 
This chapter summarises the way in which the benefits of liver transplantation 
can be estimated in the absence of firm comparative data. The same methods can 
of course be used to assess the benefits of other organ transplants. 
Survival 
To assess the benefits on survival, data concerning survival with 
transplantation have to be balanced against those for survival without 
transplantation. Four problems arise: 1) there are no data available from 
randomised studies, 2) the available data do not represent the current situation, 3) 
the differences between survival with and without transplantation may depend on 
patient characteristics and 4) the indications for transplantation may have changed 
over time. 
SURVIVAL WITH TRANSPLANTATION 
The probability of survival following transplantation can best be estimated on 
the basis of observed survival. Particularly if the probability of survival is likely to 
have changed over time, special care must be taken to ensure that such estimates 
represent the most recent situation. For liver transplant recipients, the overall 
probability of 5-year survival has improved steadily over the years, increasing from 
about 0.20 for patients treated between 1963 and 1979 to 0.64 for recipients 
treated between mid-1980 and 1988.12.13 More recently an overall 3-year post-
transplant survival probability of 0.682 was published, based on data from 8501 
recipients undergoing transplantation between October 1987 and December 
1991.14 This suggests that the spectacular improvement noted up to 1988 did not 
continue. However, it is difficult to draw conclusions here. Survival after 
transplantation is affected not only by improvements in technique, follow up 
treatment or care, but also by a number of confounding factors such as age, race, 
primary liver disease and clinical status. 14.'6 Hence, changes in the distribution of 
these factors, especially in the primary liver disease, may also change the overall 
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probability of survival. It is noted that in liver transplantation such confounding 
factors are probably more important than in heart or renal transplantation. Centre-
to-centre variability in survival rates following liver transplantation can be reduced 
by 41 % by the inclusion of indicators for patient-mix in the analysis.17 In renal 
transplantation the inclusion of such indicators are least effective, reducing 
variability by only 12%. 
To identify and correct for the simullaneous effects of changes in medical 
care and changes in the distribution of other confounding factors, both a large 
patient population and detailed data per patient are needed. When either of these 
is unavailable, correction is mostly limited to only one confounding factor at a time, 
e.g. diagnosis. Especially when evaluating the long term benefits of a technology 
on survival, such univariate analyses must lead to sub-optimal estimates. If 
numbers are too small to identify and correct for the effects of other confounding 
factors no correction can be made for e.g. the year of transplantation as a 
confounding factor. Such uncorrected survival curves do not necessarily give an 
accurate short-term survival probability for patients who had a transplantation in the 
more recent years of the period the curve was drawn for. 
SURVIVAL WITHOUT TRANSPLANTATION 
In the absence of data from a randomised clinical trial, a number of 
possibilities exists to estimate survival without transplantation (see Table 1). All 
methods have their own advantages and disadvantages and whichever method is 
chosen account has to be taken of the distribution of patient characteristics that 
affect the probability of survival, as with survival after transplantation. 
Table 1 Melhods 10 estimale survival wilhoullransplanlation'8 
1. Quasi-experimental control group 
2. Intervention delay group 
3. Formal expert judgement 
4. Historical control group 
5. Prognostic modelling 
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A quasi-experimental control group could consist of patients who fulfilled 
entrance criteria but refused therapy. Before including a patient in such a control 
group, one has to be certain that the reason for refusing therapy is not related to 
the prognosis of the patient. Often such control groups are small, leaving estimates 
with large uncertainty margins. 
Patients who are on the waiting list for the target technology could be 
included in an intervention delay control group. Such control groups are useful only 
if patients remain on the waiting list for some time and are treated in the sequence 
of entry on the list. If patients with the worst prognosis are given priority above 
patients with a better prognosis, a bias is introduced. 
Estimates of survival probability based on expert opinions will be prone to 
subjectivity and uncertainty. Subjectivity, however, can also be seen as an 
advantage, since clinical jUdgement, which is often difficult to translate into 
objective factors, will probably be taken into account. The uncertainty margins 
surrounding this method can be narrowed by using a (relatively time consuming) 
Delphi method.'· In this method a large number of experts are asked to give their 
opinion, anonymously and in writing. The results are analysed and reported back to 
the experts. They are then asked to restate their opinion, and the process 
continues until no further changes in opinion take place. However, the reliability 
and validity of the results remain difficult to test. 
It is not always easy to find reliable historical control groups. Data gathered in 
the past will not have been recorded according to a systematic protocol, limiting the 
possibility of identifying whether patients would have fulfilled the current entry 
criteria. Additionally, if large changes in medical care have occurred, the results 
may not represent the current situation. 
Sometimes a prognostic model can be used. With such a model a personal 
expected survival curve can be calculated for each patient at the time of 
transplantation, as if no transplantation had been performed. Individual survival 
curves can be combined into an aggregated curve, to produce an estimate that 
represents the average survival probability for the patient population that is to be 
assessed.'o 
For the estimation and identification of a reliable prognostic model, data on 
historical controls are most appropriate. Often such models are based on data from 
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patients with the whole range of disease stages. However, distinction should be 
made between estimation of the effect of confounders and estimation of survival. 
For estimation of the precise effect of the various confounders on survival, data 
may include patients who would not have been actual transplant candidates. For 
the precise estimation of survival probability, data from patients with the same 
stage of disease as transplant recipients should be used. Prognostic models 
combining both sources of data may introduce a false sense of reliability. 
There are several examples of prognostic models for liver disease. Dickson 
and colleagues developed a Cox proportional hazards model to predict survival for 
patients with primary biliary cirrhosis,21 often called the Mayo model. This model 
includes oedema, serum bilirubin and albumin levels, prothrombin time and age as 
variables. It has been validated several times, with good results for patient groups 
but inconsistent results for individuals. "·2' 
Other models for the estimation of survival in patients with primary biliary 
cirrhosis have been proposed by Christensen et ai, Albers et al and Rydning et 
a1.25.27 Oellerich and colleagues and Christensen and co-workers produced models 
for patients with cirrhosis.28.3o Models for patients with hepatitis B, primary 
sclerosing cholangitis and acute liver failure have also been published.31 .3' 
SURVIVAL WITH AND WITHOUT TRANSPLANTATION: THE NUMBER OF LlFE-
YEARS GAINED 
The comparison between survival with and without transplantation is one of 
average results for the whole program. A change in the distribution of patient 
characteristics, or other time dependent changes in the liver transplantation 
programme, may influence both curves differently, leading to a different number of 
life-years gained for more recent transplant recipients. One of the underlying 
reasons for such a change in patient characteristics may be the availability of 
appropriate donor organs.'5 When more or fewer donor organs become available, 
the selection of patients may change. This may change the distribution of patient 
characteristics and therefore affect both survival curves (with and without 
transplantation) separately. 
If the gain in survival is analysed for all patients with primary biliary cirrhosis 
who received transplants at Groningen University Hospital, the Netherlands, 
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between 1979 and 1990 (see chapter 4B), it is estimated that 3.5 years were 
gained by transplantation. If the more recent situation is described for these 
patients about 6.3 life years will be gained by transplantation instead of 3.5. This 
increase in the number of life-years gained is caused by an increase in the 
probability of survival with transplantation and by a decrease in the probability of 
survival without transplantation in the more recent transplant recipients. The 
decrease in survival probability without transplantation may have been caused by a 
shift in the timing of the transplantation towards a more advanced stage of disease. 
Quality of life 
Innovations may have an effect not only on survival but also on the quality of 
life. Especially for patients in the end-stage of a chronic disease, for whom a 
relatively long survival with a poor quality of life may be expected, the technology 
might affect quality of life more than survival. Here, as with survival, the effect of 
transplantation on quality of life is assessed by comparing quality of life with 
transplantation to that wilhoul transplantation. Moreover, as in the assessment of 
survival, the lack of randomised controlled double-blind trials limits empirical 
comparison. 
The assessment of quality of life, leading to a concept that enables the 
calculation of quality adjusted life-years gained, consists of at least three steps: 
measurement, translation and valuation." This section concentrates on the results 
from the measurements. 
The individual patient, his or her family and the clinical practitioner will 
probably assess the benefits of the transplantation both in terms of survival and 
also by the subjective and objective health and well-being of the patient, the 
functioning of the transplant, the length of hospitalisation of the patient, and the 
occurrence of rejection and complications. In a formal assessment of the effects of 
transplantation on patient groups these latter effects are all comprised in the 
concept quality of life, to enable comparison with other health-care facilities. This 
quality of life is preferably measured by standard validated questionnaires that are 
sensitive to the changes expected in transplant recipients. Being sensitive means 
that detailed disease-specific questions have to be answered. To make 
comparisons possible, questions need to be answered that are not of particular 
importance to the disease being investigated. Questionnaires that combine both 
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aspects are rarely available and therefore two separate questionnaires are often 
used, one directed at the general health status, and the other at more disease-
specific, or in this case transplant-specific, problems. In a number of circumstances 
it may be worthwhile to consider the use of a third questionnaire. For example 
when a value has to be assigned (normalised between zero and one) to observed 
health states, representing their relative weight between the worst and the best 
imaginable health state. In that case measurement instruments such as the 
EuroQol questionnaire or the Quality of Well-Being Scale,36.3? which allow for an 
easy translation from measurement to valuation, will be helpful. 
QUALITY OF LIFE WITH TRANSPLANTATION 
Immediately after transplantation, patients are hospitalised for some time and 
most complications occur in this period. Consequently, the effects of 
transplantation on quality of life might be quite different in the short term than in the 
long term. To identify these differences, quality of life after transplantation must be 
measured at regular intervals and special care should be taken to avoid selective 
non-response. It may be that patients who are more severely ill do not respond 
because of their physical condition and this may affect the validity of results."a 
Selective non-response because of death should be taken into account in the 
interpretation but not in the calculation of the results. 
In general, adult liver transplant recipients report good quality of life."·-40 
However, some authors report disturbances in neuropsychologic testing'O In a 
cross-sectional study in the UK it was reported that sleep was the most common 
problem and that problems with physical mobility, energy and social isolation 
decreased a year after transplantation.4 The change in health status over time was 
also addressed in a longitudinal study in orthotopic liver transplant recipients in the 
Netherlands. Before transplantation patients showed psychological distress, a low 
Karnofsky index, many physical disturbances and a low level of experienced well-
being.3a Three months after transplantation a considerable improvement was 
observed, which was maintained for one year after transplantation. 
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QUALITY OF LIFE WITHOUT TRANSPLANTATION 
Quality of life without transplantation is probably related to the stage of 
disease, and therefore data measuring quality of life without transplantation should 
be controlled for this. Unlike data concerning survival, no data can be made 
available about quality of life of historical control groups. This type of research is 
relatively new and data on quality of life have not been gathered consistently. 
Again, a second-best solution has to be found. The most practical one is to use 
quality of life experienced by patients while on the waiting list for transplantation as 
a proxy for their expected quality of life without transplantation. However, using this 
method, quality of life without transplantation will probably be overestimated, 
because it is assumed to remain steady; in reality there will probably be a time-
dependent deterioration. 
Benefits of transplantation 
If the expected quality of life is taken into account, the number of Quality 
Adjusted Life-Years (QALYs) that might be gained by transplantation can be 
calculated. The conversion from life-years to QAL Ys is made in three steps. 
First, the results of the measurements are translated into archetypal health states 
in five dimensions which represent mobility, self-care, activities of daily life, pain 
and depression-anxiety according to the EuroQol concept. 36 
Then a valuation on a scale of 0-1 is estimated for each health state. These 
estimations are based on valuations given by the general population to a large 
number of health states described in the same dimensions.42 
Finally, the duration in each health state has to be multiplied with the value 
ascribed to each health state. Thereby the valuation is used as a correction factor 
on the two survival curves. For the patients with primary biliary cirrhosis who 
received transplants at Groningen University Hospital between 1979 and 1990 life 
years without transplantation have been multiplied with a factor 0.73 (chapter 48). 
Additionally, the first three months after transplantation have also been multiplied 
by a factor 0.73, the next nine months by 0.84, the second year by 0.93 and the 
years thereafter by 0.87. The average number of QAL Ys gained by these patients 
is 3.45, compared with 3.52 life-years. Taking account of the enlarged differences 
for more recent transplant recipients the estimate is converted to 5.6 QAL Ys. 
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Discussion 
Formal assessment of benefits of existing programmes is mainly carried out 
for economic evaluations. In such evaluations the other side of the coin of efficacy 
shows costs, and these are usually high in transplantation programmes, because 
the pretransplantation screening programme and life-long treatment with 
immunosuppressive drugs are taken into account. 
Detailed information about the cost-effectiveness of medical technologies 
may support decisions on the allocation of scarce resources at several levels in the 
health-care sector. 43 On a national level, the decision regarding what proportion of 
a country's national income should be directed towards health care is at stake. 
Within health care, decisions on the reimbursement of new medical technologies or 
decisions regarding priorities towards certain diseases have to be made, as well as 
decisions on whether available resources for a certain disease should be spent on 
the treatment of end-stage patients or on prevention. For example, in the treatment 
of Hepatitis B money can be allocated to vaccination programmes or to transplant 
programmes, providing probably similar benefits in the long term. Likewise, it 
should be determined whether a new medical technology, such as liver 
transplantation, should be available for all indications. The outcome of these 
decisions may depend on whether short- or long-term effectiveness is sought. 
However, for all these decisions information is necessary. Only part of this 
information is formed by costs and benefits. Ethical considerations, legal 
restrictions and effects on equity should also be taken into account. Therefore, 
economic evaluation should be seen as a technique to offer information in a 
structured way, alongside other forms of information. 
Within economic evaluation the precise assessment of benefits plays an 
important role, and we have outlined such an assessment with respect to liver 
transplantation. It should be stressed that the perspective chosen here has been 
one in which society's values are considered rather than individual expectations. 
Nevertheless, the one cannot be considered without the other and, as such, the 
same results may also help clinical decision-makers. Using similar techniques, 
groups of patients may be identified that benefit more (or less) by a service than 
other groups," and such information may be considered - again with other 
information - in guidelines for the allocation of donor-organs in times of scarcity." 
Additionally, these techniques may help to determine the optimal timing of 
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transplantation in the course of disease.46 Such information has led to general 
recommendations for earlier referral of patients to transplant centres.15.35.47 
Finally, of course, individual patients may be affected, directly or indirectly, by 
some of the above-mentioned decisions. However, because average expectations 
for patient groups are estimated, the results of these types of analyses will be of 
limited value to the individual patient. 
In conclusion it can be stated that the assessment of the benefits of medical 
technology is crucial to providing the structured information that is needed to 
remove some of the uncertainties that always surround decision-making in health 
care. This chapter has given some methods and recommendations for such an 
assessment. 
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Chapter 48. Substirution control group: example 
A SURVEY OF THE COSTS AND EFFECTS OF LIVER 
TRANSPLANTATION IN THE LONG TERM; THE LIVER 
TRANSPLANTATION PROGRAMME OF GRONINGEN UNIVERSITY 
HOSPITAL: 1979-1991' 
Summary 
This chapter presents an example of the use of modelling in a cost-
effectiveness analysis where no contemporary control group was available. A 
medical technology assessment of the liver transplantation programme of the 
Groningen University Hospital, which was commissioned by the Dutch National 
Health Insurance Funds Council, is discussed. The results of all 152 liver 
transplantations performed between 1979 and November 1990 were analysed. The 
main objective of the study was to evaluate the long term effects of liver 
transplantation. Five years post-transplantation 59% of the adult patients were still 
alive. The survival probability highly depended on the primary liver disease. Cox 
regression was used to model survival without liver transplantation. Mortality and 
morbidity mainly occurred within the first year post-transplantation. Hereafter the 
prospects for the patients were excellent, both with regard to the chances of 
survival and to the quality of life. The costs of liver transplantation could be 
calculated only for patients with primary biliary cirrhosis and other forms of biliary 
cirrhosis, not caused by hepatitis B infection or alcohol abuse. For these patients 
the costs of a liver transplantation were estimated at DFL 263, 000 (with a 10% 
margin), 10 years of follow-up included and corrected for the costs that would have 
been made for the treatment of the liver disease. For this population of patients a 
liver transplantation costs between DFL 64,000 and DFL 79,000 per life year 
gained, 10 years of follow-up included. The major part of the costs is taken up by 
the necessary prescription of cyclosporin. The need for liver transplantation in the 
Nether/ands was estimated at between 35 and 126 transplantations per year, 
• Based on: Michel BC, Bonsel GJ, S(outhard MEA, McDonnell J, Habbema JDF. Kosten-effeclivileitsanalyse 
van levertranspfanlalie op lange termijn; he! Groningse levertransplanlatieprogramma 1979-1991. Nederlands 
Tijdschrifl voor Geneeskunde 1993; 137(19): 963-969 
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depending on indications, contra-indications, referral and the percentage of re-
transplantations. 
Introduction 
The first liver transplantation in man was performed by Starzl in the US in 
1963. The patient survived for 22 days.' Since 1979 liver transplantations have 
also been performed in the Netherlands. In the beginning only at Groningen 
University Hospital, but since 1986 also at Rotterdam University Hospital. Initially, 
the liver transplantation programme in Groningen was financed by the Dutch 
Health Insurance Funds Council on a temporary basis. In 1985 this council 
commissioned an independent assessment of the liver transplantation programme 
of Groningen University Hospital to Erasmus University in Rotterdam. They aimed 
to use the results of this assessment for the determination of the place of liver 
transplantation in Dutch heallh insurance. Such an assessment of, primarily, the 
costs and effects of a medical technology, aimed at informed political decision 
making, is often called a "Medical Technology Assessment" (MTA). In 1988 this 
assessment was completed.2,3 Because of the small number of patients with a long 
follow-up no conclusion on the long-term effects of liver transplantalion could be 
drawn. Partly because of that, the former Secretary of State for Public Heallh and 
the Health Insurance Funds Council together decided to postpone the decision and 
to instigate a second study focusing on the long-term effects of liver 
transplantation. The main resulls of this second study, completed in January 1992, 
are presented in this chapter. 4 
Patients and methods 
For every patient referred to Groningen Universily Hospital for liver 
transplantation the reason of referral, the time spent in the separate phases of the 
transplant programme, the date patients were excluded from the programme or the 
date of transplantation, and the date of death were registered. For every liver 
transplant in an adult patient the physicians at Groningen University Hospital 
collected demographic data on the recipient, and data concerning the pre-operative 
condition of the recipient, the surgery and the donor. Following transplantation, 
data on the recipient were collected at three months and at 1, 3, 5, and 10 years. 
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Also, the date and character of each episode of illness, and the ward and length of 
each stay in hospital or nursing-home following the transplantation were registered. 
In categorising the diagnoses the group "other cirrhoses" was formed. In this 
category auto-immune cirrhosis, cryptogenic cirrhosis and other forms of cirrhosis 
were included, but not cirrhosis after viral hepatitis or alcoholic cirrhosis. 
The number of episodes of illness was expressed per patient-year because not all 
patients were at risk during the whole period, due to death, re-transplantation or 
censuring. In presenting changes over time, period I (1979 to September 1987) 
was compared to period II, the period of the second study (October 1987 to 
November 1990). 
For the assessment of quality of life adult patients were asked to complete 
questionnaires, presented by personal computer, in the period July 1987 to March 
1991 5 During their annual in-hospital check-up patients were asked to sit behind 
the personal computer in a sequestered place. The computer programme was 
constructed in such a way that patients could complete the questionnaire 
independently after a short instruction by the staff-members. The questionnaire 
was completed in writing only if patients were too ill or if there were problems in the 
organisation of a computer session. Mostly, existent validated questionnaires were 
used. Some questionnaires were developed for this study. 
ANALYSES AND MODELS 
For the analysis of the probability of survival the method developed by Kaplan 
and Meier was used."'? Determinants of prognosis were evaluated by Cox 
proportional hazards models To calculate the number of life-years that might be 
gained by transplantation the expected survival without transplantation was 
estimated by modelling techniques9 .'o Survival without transplantation for patients 
with "other cirrhosis" was predicted with a model that was based on data from 
patients at the Hospital Clinic i Provincial de Barcelona who didn't receive a 
transplant (yet)." To predict survival without transplantation for patients with 
primary biliary cirrhosis a model developed in the Mayo Clinic in the US was 
used. 12 
The number of life-years that might be gained by liver transplantation was 
corrected for quality of life and expressed in "quality adjusted life-years" (QAL YS).'3 
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COSTS 
For the cost-calculation data from the first technology assessment were 
used." Adaptations were made for changes that could be deduced from the 
current data collection. New data concerning the probability of survival, the number 
of hospitalisations and the length of stay in hospital, the proportion of re-
transplantations and the number of patients in each pre-transplantation phase were 
available. Data collection for the second MTA study was completed at November 1, 
1990. 
Costs and effects were discounted by 5% annually: this means that life-years 
that are gained in the short term are valued higher than those gained in the long 
term.15 In the calculations of the costs, margins of uncertainty of 10% were used. 
Results 
Between 1979 and November 1990 in total 745 patients were referred to 
Groningen University Hospital for transplantation; 19% of these patients received a 
transplant in this period. The largest number of referrals was seen in 1983. Over 
the years the number of drop-outs in the separate phases decreased (table 1). In 
1983 9.9% of the referred patients received a transplant, in 1990 this had 
increased to 43%. In period I still 47 of the referred patients with primary biliary 
cirrhosis or "other cirrhosis" (41 %) were thought to be unfit for transplantation 
because of inferior liver function, in period II this happened only once (6%). 
Between 1979 and November 1990 152 liver transplants were received by 
134 patients, 33 of those were children. Eighteen re-transplantations were 
performed. The main indication for transplantation was primary biliary cirrhosis 
(table 2). Five years following transplantation 59% of the adult recipients were still 
alive. The main mortality was seen in the peri-operative period and within the first 
year. Patients who survived the first year had a probability of 88% to survive 5 
years. 
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Table 1 Annual inflow of patients (adults and children) in separate phases of the liver 
transplantation programme at Gronlngen University Hospital, 1977 to end 
1990. 
R-phase' PC-phaseb A-phase' GL-phased LTX-phasee 
1977 2 1 0 
1978 9 1 0 0 1 
1979 21 7 4 4 4 
1980 23 7 5 5 3 
1981 43 24 5 5 5 
1982 84 33 19 11 11 
1983 101 49 25 9 10 
1984 91 32 27 8 6 
1985 78 24 16 11 7 
1986 59 27 27 13 11 
1987 57 27 18 18 15 
1988 57 35 31 20 14 
1989 60 39 31 22 27 
1990 60 28 24 34 26 
Total 745 140* 
8 R-phase = referral: patients are referred to Groningen University Hospital for liver 
transplantation 
b PC-phase = possible candidate: transplantation is being considered, in-hospital 
evaluation. 
, A-phase = acceptance: patients are accepted for transplantalion and await the 
right timing of transplantation in their course of illness. 
d GL-phase = green light: patients are on the Eurotransplant waiting-list waiting for 
an appropriate donor. 
e LTX-phase = liver transplantation: patients receive a (primary) liver transplant 
* 134 primary transplantations + 5 transplantations that were performed in 1990 after November 1st + 1 
transplantation performed in London in 1978 
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The primary liver disease had a strong influence on survival following liver 
transplantation. Patients with biliary atresia (mainly children) had the best 
prognosis, patients with "other cirrhosis" the worst, mainly because of a large peri-
operative mortality (figure 1 a). The age of the patient and the severity of the liver 
disease, expressed in the Child-Pugh score,'6 only had a small influence on post-
transplant survival. 
Table 2 Demographic and medical data on adult patients at the time of their first 
transplantation. Comparison of period I (1979 to October 1987) and period /I 
(October 1987 to November 1990). 
Period I Period II 
Number of patienls 59 42 
~iagnosis: Malignanllumour (%) 2 (3%) 1 (2%) 
Primary biliary cirrhosis 24 (41%) 11 (26%) 
Olher cirrhosis 22 (37%) 10 (24%) 
Primary sclerosing cholangilis 3 (5%) 5 (12%) 
Olher diagnoses 8 (14%) 15 (36%) 
Gender: number of females (%) 43 (73%) 27 (64%) 
Age: average in years (SO) 40.8 (12.3) 42.6 (11.9) 
Ouralion of illness: average in years (SO) 7.2 (4.0) 7.4 (5.8) 
Hepalorenal syndrome: number (%) 26 (44%) 33 (79%) 
Portal hypertension: number (%) 51 (86%) 35 (83%) 
Child-Pugh class '6: class A (%) 16 (27%) 5 (12%) 
class B 32 (54%) 16 (38%) 
class C 11 (19%) 21 (50%) 
Karnofsky-score: average (SO) 63.1 (17.7) 55.5 (25.8) 
ALA TIS GOT (0 - 40 U/L) 124.8 (81.6) 153.7 (143.5) 
Bilirubin lola I (3 - 26 mmoJlL) 128.5 (160.5) 195.0 (196.6) 
Alkaline phosphalase (13 - 120 UiL) 600.7 (650.5) 473.2 (428.3) 
y-Glulamyl Iranspeplidase (0 - 65 U/L) 322.5 (366.3) 230.0 (296.5) 
Albumin (34 - 47 giL) 33.3 (6.4) 29.1 (6.6) 
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Figure 1a SU/vival after liver transplantation in 134 patients (adults and children) in the 
period 1979 - November 1990 by diagnosis (A: biliary atresia, n = 16 all 
children; 8 = other diagnoses n = 45; C = primary biliary cirrhosis n = 35; 0 = 
other cirrhosis n = 38, including 6 children) 
1 
A 
B 
1 2 3 4 5 6 7 8 9 10 11 12 
tirm after transplantation (years) 
Figure 1 b Survival after liver transplantation in 101 adult patients, comparing period I 
(A) to period /I (8) 
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During the liver transplantation programme a clear improvement of the 
probability of survival was seen for adult patients (figure 1 b). A strongly improved 
probability of survival from 3 months post-transplantation onwards was seen in 
period II. Peri-operative mortality and mortality within the first 3 months did not 
change. 
The proportion of re-transplantations to primary transplantations was identical 
in both periods. But the time between the first and the second transplantation 
clearly decreased, from, on average, 11.6 months in the first period to 1.6 months 
in the second. In many patients the transplant functioned well from three months 
post-transplantation onwards. Liver functions improved until 5 years post-
transplantation and reached normal values in a large fraction of the patients (table 
3). 
Table 3 Function of the liver transplant, liver cell decay and chalestasis in adull 
patients in the long term. Median value (percentage of patients outside 
normal range). 
Liver functions Pre- 3 months 
(normal range) operative after surgery 
n = 109' n = 78' 
SGOT/ALAT (0·40 U/L) 116.0 (86%) 35.0 (43%) 
y-GT (0-65 U/L) 183.0 (76%) 230.0 (74%) 
LDH (114-235 UlL) 252.0 (61%) 279.0 (73%) 
Alkaline phosphatase (13-120 U/L) 344.0 (87%) 152.5 (62%) 
Bilirubin total (3-26 mmollL) 68.0 (73%) 21.5 (41%) 
Albumin (34-47 giL) 32.0 (62%) 38.0 (21%) 
Prot rom bin time (0-16 sec) 15.0 (31%) 12.8 (4%) 
Antithrombin III (>80%) 72.0 (60%) 117.0 (4%) 
1 except protrombin time n = 110; albumin n = 111 
, except protrombin time n = 54; antithrombin III n = 57; LDH n = 77 
3 except protrombin time n = 16 
5 years after 
surgery 
n = 17' 
24.0 (29%) 
21.0 (29%) 
231.0 (41%) 
60.0 (29%) 
16.0 (12%) 
41.0 (0%) 
13.0 (0%) 
103.0 (12%) 
On average patients experienced 10 episodes of illness per patient-year 
during the first year post-transplantation. After the first year this number decreased 
to, on average, 1.2 episodes of illness per patient-year in the second year. In later 
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years a further decrease in the average number of episodes was seen to 0.3 
episodes in the ninth year (in 10 patients). 
Patients spent much time in hospital during the first year following 
transplantation (on average 2.4 months per patient), afterwards this decreased to 
on average 3.2 days per patient in the sixth year. In period" patients, on average, 
spent more time on artificial respiration and in the Intensive Care unit than during 
period I. 
QUALITY OF LIFE AND LIFE-YEARS GAINED 
Before transplantation patients reported a moderate quality of life (table 4) 
The main complaints were related to the liver disease, frequent sleep disorders 
were reported and there were restrictions in mobility and energy. Candidates for 
transplantation were (on average) somewhat frightened and rather depressed. But 
they still had a fair ability to take care of themselves. From 3 months after 
transplantation the physical, psychological and subjective health-state improved, 
and one year after transplantation a stable situation had established that was 
almost identical to the level of an average population of healthy adults, except for 
the number of hours that was daily spent in school or at a paid or unpaid job. 
The average number of life-years gained per patient by liver transplantation 
was estimated by comparing the observed survival with transplantation to the 
estimated survival without for patients with primary biliary cirrhosis and "other 
cirrhosis" separately, figure 2. With this method it was calculated that a patient with 
primary biliary cirrhosis gained on average 3.2 years in the first 10 years after 
transplantation (with discounting). A patient with "other cirrhosis" gained 0.9 years 
during the same follow-up. This difference is mainly caused by a much lower 
survival following transplantation for patients with "other cirrhosis". After correction 
for quality of life the average number of life-years (QAL Ys) that was gained by 
patients with primary biliary cirrhosis and "other cirrhosis" together was 3.5 years 
with a time-limit of 10 years and 6.9 years within a follow-up of 25 years. 
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Table 4 Quality of life in 70 patients before and following liver transplantation in the 
period 1987 -1991.-
Questionnaire completed" 
Reference pre- after 3 after 1 after 5 
valuesc operative months year years 
(SD) 
Questionnaired (n = 43) (n = 31) (n = 25) (n = 7) 
Daily activities (ADL) 16 1-10 (;;,9) 8.3 ( 1.9) 8.8 9.4 9.9 
Hours work/school daily 0-12 (i8) 1.9 ( 2.9) 1.4 3.4 4.4 
Karnofsky 17 0-100 (;;,90) 61.4 (19.6) 69.4 89.2 87.7 
Anxiety (STAI) 18 80-20 (,;37) 43.0 (10.8) 35.2 31.7 30.3 
Depression (SDS) 19.20 100-25 (,;35) 43.4 ( 8.8) 35.7 32.6 36.6 
Well-being (IWS)21 2.1-14.7 (>12) 8.9 ( 3.2) 12.6 12.6 13.6 
NHP_DA22.23 
-mobility 100-0 (,;15) 36.2 (28.5) 27.2 15.2 17.1 
-pain 100-0 (,;15) 18.9 (26.8) 11.8 5.2 11.7 
-energy 100·0 (,;15) 67.9 (39.7) 20.5 4.9 8.7 
-sleep 100·0 (,;15) 42.5 (35.9) 16.8 13.5 5.9 
-social isolation 100-0 (,;15) 18.8 (23.1) 7.5 8.8 5.5 
-emotional reaction 100·0 (,;15) 21.2 (22.7) 8.0 4.4 2.9 
Data were collected in the period July 1987 - March 1991: 182 questionnaires were 
completed by 70 patients, 11 of these patients had not received a liver transplant by 
March 1991 yet; 23 other questionnaires were not completed, 2 because of refusal 
by the patient, 15 because of problems in organising a session for the patient, 6 
because the patient was too ill. 
Standard deviations are only mentioned for pre-operative values. For later scores the 
standard deviation was identical or smaller. 
Range of possible scores (reference values normal population); worst score left, best 
score right 
ADL = activities of daily life; STAI = state trail anxiety inventory; SDS = self rating 
depression scale; IWB = index of well-being; NHP-DA = Nollingham health profile, 
Dutch adaptation 
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Costs of liver transplantation, including 10 years of after-care, were estimated 
at DFL 319,000 for patients with primary biliary cirrhosis and "other cirrhosis" (with 
a margin of uncertainty of 10%). Opposite these costs were the savings due to the 
disappearance of the costs that would have to be made for treatment of the liver 
disease, approximately DFL 56,000. The differential costs were DFL 263,000 per 
patient (with a margin of uncertainty, discounted), including 10 years of after-care. 
Per life-year gained liver transplantation costs between DFL 64,000 and 
DFL 79,000 including 10 years after-care for patients with primary biliary cirrhosis 
and "other cirrhosis". After correction for quality of life, one OAL Y costs between 
DFL 69,000 and DFL 84,000 with a time-limit of 10 years. Costs of cyclosporin still 
play an important role. If the price or the dosage of cyclosporin would be halved, 
cost-effectiveness would improve to between DFL 56,000 and DFL 69,000 per 
OAL Y gained for patients with primary biliary cirrhosis or "other cirrhosis". 
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THE NEED FOR LIVER TRANSPLANTATION IN THE FUTURE 
The need for liver transplants in the future depends on the contra-indications, 
the probability of a re-transplantation, the indications and the referral-policy. It is 
not to be expected that contra-indications and the probability of are-transplantation 
will change drastically in the coming years. Within the indications, hepatitis Band, 
to a lesser extend, acute liver failure might cause an increase in the need for 
transplant capacity. Based on the incidence of both diseases it is to be expected 
that minimally 4 and maximally 47 transplants a year will be performed for these 
indications. 
If liver diseases are evenly spread over the Netherlands, referral to Groningen 
University Hospital has not been optimal so far. Certain districts were strongly 
represented, like Friesland (5 transplants I million inhabitants in 1988) and Drenthe 
(3.8 transplants I million inhabitants in 1988); other districts were badly represented 
like Zeeland (0.9 transplants I million inhabitants in 1988). A more evenly spread 
referral policy could cause an increase in the number of transplantations, if there is 
no over-treatment in the northerly districts. 
Based on these assumptions it is estimated that annually between 35 and 
126 liver transplants will be needed. 
Discussion 
Long-term results of liver transplantation appear to be very good. If a patient 
survives the first year following transplantation his or her perspectives are 
excellent. 
Over the last years clear changes have taken place in the Groningen 
University Hospital liver transplantation programme. Firstly, less patients drop out 
of the programme in the pre-transplantation phases. This could indicate an 
improved referral to Groningen University Hospital or more liberal indications used 
by Groningen University Hospital, with less weight on contra-indications. Secondly, 
the probability of survival following hospitalisation is better than before. Because 
this improvement only shows after 3 months, an improved after-care and treatment 
with cyclosporin (since the end of 1985) probably play an important role in this. 
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Other centres also saw an improvement in survival after the introduction of 
cyclosporin. 25 Thirdly, a change in the indications for liver transplantation took 
place. Hepatitis B and acute liver failure were added to the indications on a limited 
scale. 
It can be expected that the number of liver transplantations in the Netherlands 
will increase somewhat in the future. The number of liver transplants, with 2.7 
transplants per million inhabitants in 1990, is lower than in the rest of Europe. In 
West-Germany, AUstria and Belgium this number is 5.0, 10.5 and 14.0 
respectively.'··27 In the calculation of these numbers no account is taken of the 
sometimes high percentage of patients that are referred to specialised centres from 
abroad: such flows of patients will influence the number of transplants per million 
inhabitants of both the referring and the receiving country. Other explanations for 
these differences can be found in epidemiological differences (hepatitiS B, alcohol), 
the policy regarding the acceptance of patients, especially with malignant tumours 
or hepatitis B, and in age-limits. 
In 1990 73 donor livers became available for transplantation in the 
Netherlands, whereas in the future between 35 and 126 livers will be needed.'8 1t is 
not unthinkable that a shortage in donor-livers will occur if an increase in need is 
combined with a stable supply. 
The costs of liver transplantation could be calculated with a higher precision 
in the study presented here than in the first study, because more data concerning 
long-term effects were avaitable and because Groningen University Hospital clearly 
passed the starting period. In the first study costs per life-year gained were 
estimated at between DFL 47,000 and DFL 133,000. Now this range could be 
adjusted to between DFL 64,000 and DFL 79,000 per life-year gained. 
In recent years more voices have been heard demanding that considerations 
concerning costs and effects will be allowed to play an important role in the 
judgement of new medical technology. The committee "Choices in Care" 
recommends the use of, amongst others, efficacy and efficiency in the decision 
whether or not to include certain technology in baseline insurance." The report 
"Medical actions at cross-roads" recommends the introduction of new technology 
on a limited scale, followed by an evaluation in clinical practice before a large scale 
introduction is done.3o This procedure was followed in liver transplantation. It was 
introduced (and financed) on a limited scale and the decision on whether or not to 
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include it in baseline insurance was postponed until the inventory of its costs and 
effects was completed. Meanwhile the Health Insurance Funds Council has offered 
a recommendation, based on the MTA-report, to the Secretary of State for Public 
Health. A decision about the inclusion of liver transplantation in the national 
sickness fund is expected soon. 
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Chapter 5. Complementation and extrapolation of trial rosuJ(s 
ECONOMIC ASPECTS OF TREATMENT WITH CAPTOPRIL FOR 
PATIENTS WITH ASYMPTOMATIC LEFT VENTRICULAR 
DYSFUNCTION IN THE NETHERLANDS' 
Summary 
Tile objective of Ihe sludy presenled in Ihis chapler is 10 eslimale cosls and 
effecls of preventive Irealmenl wilh caplopril compared 10 the current treatmenl 
policy in patients with asymptomatic left ventricular dysfunction after a myocardial 
infarction. Estimates of effects are based on the results from Ihe SAVE-trial. Costs 
are estimated on the basis of current Ireatmenl patterns in four Dulch hospilals. All 
knowledge is incorporated in a mathematical model extrapolating the SA VE-results 
10 20 years and complementing the SA VE-results with cost data. Captopril 
treatment is expected to increase survival at certain costs. The average additional 
costs per patient are estimated at DFL 2,491 in 4 years and at DFL 8,723 in 20 
years of trealmenl. Cosls per additional survivor after four years are estimaled al 
DFL 69,126. After exlrapolation of Ihe resulls of Ihe SA VE trial 10 20 years, cosls 
per life year gained can be estimaled al DFL 15,799. From univariale sensitivity 
analysis it appears Ihal Ihe resulls are highly sensitive for Ihe costs of Irealmenl 
wilh caplopril and Ihe occurrence and prevention of clinical heart failure. Varying all .. 
estimales randomly belween upper and lower limils - in 5000 simulations - an 
estimale of cosls per life years gained of DFL 15,729 is made for 20 years of 
trealmenl, wilh 95% of all estimales between DFL ° and DFL 50,000. On a national 
level undiscounted costs are expected to increase up to approximately 
DFL 42 million annually during the first 40 years after introduction of the preventive 
strategy. 
Based on Michel BC, AI MJ, Remme WJ, Kingma JH, Kraglen JA, Nieuwenhulzen R van, Houl BA van. 
Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in the 
Netherlands. European Heart Journal. Accepted for publicalion. 
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Introduction 
Heart failure is a relatively common disease in the Netherlands. With a 
prevalence of 13.5 per 1000 men and 8 per 1000 women between 35 and 85 years 
of age, it is estimated that heart failure is present in more than 80,000 personsY 
In the near future this number will probably even increase due to the expected 
increase in the number of elderly where heart failure is relatively more prevalent. 1•3 
Next to this demographic factor, a further reduction in early mortality after 
myocardial infarction is likely to cause an additional increase in the prevalence of 
heart failure. 1 
Due to the high prevalence of the disease in the Dutch population, successful 
strategies aimed at a reduction of the progression, the incidence or the prevalence 
of symptomatic heart failure will have large consequences. 
Detection and treatment of risk factors - like hypertension, coronary artery 
disease, diabetes, obesity, serum cholesterol and smoking - are examples of 
strategies that may delay or even prevent the progression to symptomatic heart 
failure. Here changes in life style, screening of high risk individuals and optimal 
treatment of risk factors will probably have their effect. Additional benefits may be 
expected from new medical strategies. In this respect the introduction of 
ACE-inhibitors in the 1980s already had a major effect on the prevalence and costs 
related to heart failure. It has been estimated that treatment with ACE-inhibitors for 
patients with symptomatic heart failure improves survival and decreases costs by 
postponing the progression to the more advanced - and more costly - stages of the 
disease: Recently, the SAVE trial and the SOlVD Prevention Trial have shown 
that treatment with ACE-inhibitors can also delay or prevent the occurrence of 
symptomatic heart failure 4 .5 Moreover, the SAVE trial, which investigated patients 
with a diminished left ventricular function after a myocardial infarction, also showed 
a significantly lower death rate by cardiovascular causes: 
In the Netherlands, preventive therapy with ACE-inhibitors is not common yet. 
In view of the economic aspects of this form of therapy several questions can be 
raised. Preventive treatment may be lifelong and it may involve large numbers of 
patients. Hence, costs may be considerable. On the other hand, there also is a 
potential to generate savings. Under the current treatment policy annually almost 
429 million Dutch Guilders (about 200 million ECU) is spent on the treatment of 
symptomatic heart failure, which equals 1.1% of the total costs of Dutch health 
care.6 
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In this article the results of the SAVE trial are used to estimate the balance 
between costs and effects of preventive treatment with captopril, compared to the 
current strategy, for patients with asymptomatic left ventricular dysfunction after a 
myocardial infarction. Also the macro-economic consequences of an initiation of 
preventive treatment on a nation-wide level are estimated. 
Methods 
The SAVE trial evaluated the effects of a preventive treatment with captopril 
in two groups of about 1100 patients with asymptomatic left ventricular dysfunction 
after myocardial infarction. The follow-up of the trial was 42 ± 10 months, 82 
percent of the patients were males and the average age of the patients was 60.' 
This trial showed that long-term administration of captopril is associated with an 
improvement in survival, a decrease in the incidence of symptomatic heart failure 
and a decrease in the number of reinfarctions.7 
In the present study two base line scenarios were defined for the comparison 
of costs and effects between preventive treatment with captopril and the current 
strategy. The first scenario models the current treatment policy. In this scenario the 
probabilities concerning effects are obtained from the results reported for the 
placebo-arm of the SAVE trial. The second scenario models the situation in which 
captopril is subscribed. Here, the parameters concerning effects are taken from the 
results in the captopril-arm of the SAVE-trial. 
To compare the costs and effects of these two scenarios a mathematical 
model was built. There were two reasons why this modelling technique was 
chosen. 
First, data on costs were not made available in publications about the SAVE trial. 
Therefore, different sources of data had to be brought together and for such 
purpose a model is a suitable instrument. 
The second reason is that preventive treatment can be seen as an investment for 
the future and that consequently, the balance between costs and effects needs to 
be assessed over a longer period than the trial. Again, a mathematical model is a 
suitable instrument to make such an extrapolation. 
The model that was used is a so called Markov chain model, that incorporates 
data about the current strategy, the effects of captopril, the costs of treatment and 
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the epidemiology related to the patient population studied. With regard to the 
effectiveness of the therapy the model is mainly based on data from the SAVE 
triaI4 •8.9 With respect to the current treatment policy, the costs and the 
epidemiology, priority was given to data specific for the Dutch situation. 
Two separate analyses were made. In the first analysis the results after four 
years were evaluated and compared to those of the SAVE trial using the 
cumulative event rates that were presented by Pfeffer et al.4 In the second analysis 
the results were extrapolated to a period of 20 years. 
THE MODEL 
Figure 1 presents an outline of the model. The model evaluates the 
diagnostic and therapeutic events that occur in 100 patients with the characteristics 
of the patients in the SAVE trial during 4 (the first analysis) or 20 (the second 
analysis) consecutive years. For the first 4 years of treatment the model copies the 
SAVE results as closely as possible. After that, the model extrapolates the results 
with the assumption that the average effectiveness and treatment policy over the 
first four years will continue in the later years of therapy. 
The model describes events and treatments for 100 patients who experienced 
a recent myocardial infarction but have no symptoms of heart failure. The layout of 
the model is identical for both scenarios with respect to the events that may occur 
and the treatments that are given. It is assumed that additional echocardiography 
(and sometimes radioventriculography) will have to be performed in patients who 
did not receive echocardiography as a routine follow-up of their infarction. The 
costs for this additional assessment are included in the captopril scenario. During 
the first year, patients with a-symptomatic heart failure experience normal follow-up 
of their index infarction, including analysis of cardiac ischaemia with exercise tests 
or thallium scans, angiography if one of these tests is positive, and cardiac 
intervention if the angiography indicates that this might be necessary, in both 
scenarios. Because the policy on the timing of interventions differs for separate 
hospitals and in separate periods, depending on the waiting list and on the urgency 
of the indication, no distinction is made as to whether the analysis for cardiac 
ischaemia and subsequent interventions were performed during the initial 
hospitalisation phase for the index infarction or during the follow-up phase, 
requiring readmission for the intervention. All surviving patients are assumed to 
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have a follow-up of their primary infarction consisting of, on average, 4 out-patient 
consultations, each including an electrocardiogram, medication and some basic 
laboratory tests. Some patients will also follow a cardiac rehabilitation programme. 
During subsequent years some patients will be re-evaluated for their cardiac 
function with an echocardiography and I or a radioventriculography. In some 
patients with stable angina pectoris, cardiac ischaemia will also be analysed and, if 
necessary, treated. The model includes unstable angina pectoris, re-infarction, 
cerebrovascular accident and symptomatic heart failure as the main cardiovascular 
complications. Every year a patient can have more than one complication. The 
events and treatments patients may encounter after re-infarction are shown in 
figure 2. The events and treatments for patients with unstable angina pectoris are 
identical, except for the thrombolysis. 
After developing symptomatic heart failure, patients enter a separate part of 
the model. This part of the model was built earlier to estimate costs and effects of 
ACE-inhibitors for symptomatic heart failure, and includes the same cardiovascular 
complications as the main model.'·10 Here patients are categorised by their 
condition according to the New York Heart Association classification. It is 
emphasised that patients in this part of the model who subsequently become 
asymptomatic do not re-enter the main model. As long as they have no symptoms 
they remain in New York Heart Association class I. Table 1 gives an overview of 
the data included in the model. 
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Figure 1 Outline of the simulation model. eVA = cerebrovascular accident; RI = reinfaction; UAP = unstable angina pectoris; NYHA = 
classification by the New York Heart Association. 
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Table 1 Minimum and maximum transition probabilities in the baseline scenario. 
current strategy preventive treatment capt. a 
% min max % min max 
Echocardiography 
1st year 90 80 100 100 
next years 37.5 25 50 
Radioventriculography 
1 st year 22.5 5 40 
next years 11.3 2.5 20 
Exercise tolerance test (En) 
1st year 90 80 100 
next years 40 20 60 
percentage of En with thallium 20 10 30 
Intervention 
1st year 10 5 15 
next yearsb 3 1 5 
percentage CABG/PTCA' 100 75 125 
Percentage angiographyl 225 150 300 
interventionsd 
Patients' rehabilitation 11 
after PTCA 25 20 30 
afterCABG 50 45 55 
after uncomplicated infarction 33 25 40 
Percentage of patients with 55 40 70 
unstable angina who underwent 
subsequent angiography 
Reinfarctione 
in 1st year 8.5 6.9 10.1 7.5 6.0 9.0 
in 2nd year 4.4 3.1 5.7 2.5 1.5 3.5 
in 3rd year 3.5 2.3 4.7 2.5 1.5 3.5 
in 4th year 3.1 1.7 4.5 2.0 0.9 3.1 
in following years 3.7 1.4 5.9 2.3 0.6 4.1 
Percentage of patients with a 32.9 22.9 42.9 
reinfarction treated with 
thrombolysis 
Cerebrovascular accident (CVA) 2 0.8 3.2 
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% min max % min max 
Symptomatic heart failure (CHF) 
in 1st year 22.0 19.6 24.4 16.0 13.9 18.2 
in 2nd year 5.1 3.7 6.5 6.0 4.5 7.5 
in 3rd year 6.1 4.6 7.7 2.8 1.7 3.9 
in 4th year 6.5 4.5 8.5 6.5 4.5 8.5 
in following years 5.9 3.1 8.8 5.1 2.4 7.8 
inflow in NYHA III 30 25 35 
NYHAIV 20 15 25 
Death 
, 
b 
c 
d 
, 
after coronary angiography 0.02 0.01 0.03 
after En 0.02 0.01 0.03 
after PTCA 12 1 1 2.1 
after CABG 12 3.6 1.1 3.6 
after unstable angina pectoris 11 9 13 
after reinfarction 22 15 35 
before diagnosis and therapy' 60 50 70 
after CVA In hospital 23.9 15 30 
CHF NYHA I 7.5 2.5 12.5 
CHF NYHA II 12.5 7.5 17.5 
CHF NYHAIII 15 10 20 
CHF NYHAIV 40 25 45 
Preventive Irealmenl wilh caplopril. Only values Ihal were differenl from Ihose used in 
Ihe "currenl slralegy" are presenled. 
In patienls wilhoul unslable angina pecloris, re-infarction or symplomatic heart failure 
This means Ihal in Ihe baseline scenario Ihe number of CABGs was equal 10 Ihe 
number of PTeAs. 
Tilis means Ihal in Ihe baseline scenario Ihe number of angiographies was 2.25 times 
Ihe number of inlerventions. 
For unslable angina pecloris Ihe occurrence in bolh slralegies is assumed 10 be 
identical 10 Ihe occurrence of re-infarction in Ihe preventive Ireatmenl slralegy.7 
This means Ihal il is assumed Ihal in Ihe baseline scenario 60% of IIle patienls who 
die afler a reinfarction will do so before cosls are made for diagnosis and Iherapy. 
EFFECTS AND EPIDEMIOLOGICAL PARAMETERS 
The two scenarios differ in terms of the probabilities concerning survival, the 
development of symptomatic heart failure, and the incidence of myocardial 
infarctions. These differences are based on the resuits of the SAVE trial 4 The 
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probabilities related to the incidence of cerebrovascular accidents and unstable 
angina pectoris are similar in both scenarios.? In the 20 year extrapolation effects 
are expressed in terms of life years gained. In the 4 year analysis effects are also 
expressed in terms of additional survivors, because the period is rather short to 
give a reliable estimation in terms of life years gained. 
With respect to the survival probabilities distinction is made between 
cardiovascular and non-cardiovascular causes of death. The cardiovascular death 
rates are based on the results of the SAVE trial4 The non-cardiovascular death 
rates, with a correction for cardiovascular mortality, are based on the survival 
tables of the Dutch Central Bureau of Statistics (CBS). 13,'4 The time-dependent 
death rate due to a cerebrovascular accident is calculated according to Niessen et 
al.'5 
The probabilities that are relevant to the symptomatic heart-failure part of the 
model are taken from a previous study addressing the use of ACE-inhibitors in 
symptomatic heart failure. For that study the results of the SOlVD Treatment Trial 
were used.'6 To correct for the differences between trial results and daily practice it 
was assumed that 85% of the patients with symptomatic heart failure are treated 
with ACE-inhibitors and that only 60% of these patients benefit from this treatment 
according to the effectiveness seen in the SOlVD treatment trial. 
COSTS 
Costs were calculated from a societal point of view. Cost calculations were 
based on estimates of real costs, but limited to the medical costs of both 
treatments. Non-medical costs, direct and indirect (due to production losses), were 
not taken into account. 
Information on the current diagnostic and therapeutic policy after myocardial 
infarction in the Netherlands was gathered by studying the literature and by a 
review of current practice in four non-academic hospitals, with between 424 and 
1080 beds each (the average Dutch hospital has 422 beds). All cardiovascular 
events and all diagnostic or therapeutic actions were expressed in terms of units of 
resource use and multiplied with estimates of unit costs for the Netherlands. Costs 
of medication were based on officially published purchase prices for pharmacists.'s 
Because it is estimated that 65% of the captopril used in the Netherlands is 
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imported against lower costs, the costs of treatment with captopril were adjusted 
for this. 
Table 2 Cost-estimates included in the model 
Echocardiography17 
Radioventriculography 17 
Treatment with captopril" 
Exercise test11 
Thalliumscan (tariff) 
Coronary angiography19 
PTCA" 
CABG" 
Rehabilitation ".'0 
Follow-up after myocardial infarction 
1st year 
next years 
Unstable angina pectoris 
uncomplicated" 
Additional follow-up after unstable 
angina pectoris 
Reinfarction uncomplicated" 
Extra follow-up after reinfarction 
1st year 
next years 
Thrombolysis atter reinfarction (r-TPA)" 
Cerebrovascular accident 
patient dies in hospital" 
patient survives6,21 
Symptomatic heart failure' 
NYHAI 
NYHAII 
NYHAIII 
NYHAIV 
Costs in DFL 
1101.50 
1320.00 
11,846.68 
1121.00 
1923.10 
1 2,825.00 
19,000.00 
1 27,230.00 
11,000.00 
1 1,533.60 
1774.35 
1 4,608.00 
1450.50 
1 9,729.00 
1380.00 
1759.00 
1 2,500.00 
1 8,908.00 
f 45,300.00 
1 3,828.00 to f 6,483.00 
f 7,818.00 to f 9,313.00 
119,261.00 to 116,776.00 
169,508.00 to 144,921.00 
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Table 2 presents an overview of the cost-estimates that are used in the model. 
COST-EFFECTIVENESS 
The cost-effectiveness of captopril treatment is defined as the additional costs 
that are made in the new scenario compared to the current scenario, divided by the 
number of additional survivors or life years that are gained (L YG) in the new 
scenario compared to the current scenario. 
costScapfopril - costSclirrenlstrategy 
LYG captoprlf LYG current strategy 
Here, this cost-effectiveness ratio is calculated in two ways. The cost 
effectiveness ratios after four and twenty years are estimated in terms of the costs 
per life year gained. This is calculated as the difference in costs made during 4 (20) 
years divided by the difference in life years gained in those 4 (20) years. When 
addressing the results after four years emphasis is placed on the costs per 
additional survivor after four years. This is calculated as the difference in terms of 
costs made during those four years divided by the difference in survival after four 
years. Both costs and effects are discounted by 5%, according to the guide-lines 
for cost-effectiveness analyses from a societal point of view.22 
SENSITIVITY ANALYSIS 
Two techniques are used to assess the uncertainties surrounding the 
baseline outcomes. The first technique, an univariate sensitivity analysis, 
addresses the sensitivity of the resulting cost-effectiveness ratio with respect to the 
various estimates by varying the estimates one by one. In the second technique, a 
multivariate sensitivity analysis, all estimates are varied simultaneously. For this 
multivariate sensitivity analysis upper and lower estimates were defined for all 
underlying estimates. The estimates concerning costs were surrounded with 
uncertainty margins of plus and minus 10 percent. The estimates concerning 
effectiveness were converted into 95% confidence intervals on the basis of the 
SAVE trial. Subsequently 5000 simulations were run, each leading to different cost-
effectiveness ratios for the results after 4 respectively 20 years. By reporting the 
108 
Complementation and extrapolation of trial results 
distribution of costs, effects and cost-effectiveness ratios an impression is obtained 
of the reliability of the estimates. 
CONSEQUENCES ON A NATIONAL LEVEL 
The estimation of the consequences of the introduction of a preventive 
treatment policy on a national level is based on the intermediate population 
forecasts made in 1993 by the Dutch Central Bureau of Statistics." It is assumed 
that the incidence of primary myocardial infarctions and reinfarctions together 
remains stable at 0.2% annually and that 7.25% of all infarctions are due to 
reinfarction." No discount factor is used in the evaluation of the consequences on 
a national level. 
Results 
CONSEQUENCES ON A PATIENT LEVEL 
If preventive treatment with captopril is introduced in a patient population, the 
model predicts effects that are comparable to the results of the SAVE trial. The 
model estimates a cumulative survival after 4 years of 74.8% in the current Dutch 
strategy and 79.2% after introduction of the new strategy, as compared to about 
73.5% and 78.1 % in the SAVE trial. 4 The model also estimates that the costs of 
medication will increase with DFL 4,937 per patient, whereas the costs of 
concomitant treatment will decrease with DFL 2,446 per patient. Consequently the 
total costs per patient are estimated at DFL 2,491 per patient after four years. 
Overall survival (after discounting) is estimated to increase from 61.5% to 65.1 % 
after four years and so, the additional costs per additional survivor after four years 
are estimated at DFL 69,126. Additionally, it can be estimated that during the first 
four years, on average, 0.11 life years will be gained by preventive treatment. 
Consequently, the additional costs per life year gained during the first four years 
are estimated at DFL 22,887. 
When extrapolating the results to 20 years, it is estimated that without 
captopril 9.4% of the patients with asymptomatic left ventricular dysfunction after a 
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myocardial infarction will still be alive. With captopril this is expected to improve to 
12.8%. Additionally, it is estimated that, on average, 0.55 life years per patient will 
be gained. Finally, it is estimated that the total costs of treatment according to the 
current strategy will be DFL 59,419 per patient. With the preventive treatment 
policy used in the SAVE trial this amount is expected to increase to DFL 68,142. 
This results in an estimate of cost per life year gained of DFL 15,799. 
SENSITIVITY ANALYSIS 
The results estimated by the model are surrounded by several uncertainties. 
To evaluate those, all variables were changed one by one to ascertain the 
influence of each variable on the outcomes. This procedure shows that the 
estimation of the cost-effectiveness is extremely sensitive to the occurrence and 
prevention of clinical heart failure and the costs of treatment with captopril. For all 
other variables a change of 10% in the value of the variable results in a change in 
the 20 year cost-effectiveness ratio of less than DFL 1,200. In the baseline analysis 
it was assumed that 65% of the current consumption of captopril in the Netherlands 
is imported at a lower price. The argument can be made that this lower price of the 
import-drug is a better reflection of the price as it would be in a market of free 
enterprise, thereby representing societal costs more closely. If that argument is 
followed average additional costs after 4 years can be estimated at DFL 1,947 per 
patient, and the costs per additional survivor after 4 years at DFL 54,037. 
Concurrently, the additional costs per patient after 20 years are estimated at 
DFL 7,492 and the costs per life year gained at DFL 13,569. 
In the baseline analysis it was also assumed that a high percentage (90%) of 
patients receiving standard care would have an echocardiography after their index 
infarction. If this percentage was to lower to, for example, 50% the cost-
effectiveness ratio would be a little less favourable: 72,015 per additional survivor 
at four years and 15,961 per life year gained at 20 years. 
In the 5000 simulations of the multivariate analysis the costs and effects vary 
according to the distributions shown in figure 3. The distributions of the cost-
effectiveness ratio's are shown in figure 4. With respect to the four-year results the 
median cost-effectiveness ratio is DFL 69,651 per additional patient alive. Ninety-
five percent of all estimates have a cost-effectiveness ratio between DFL 0 and 
DFL 240,000. With respect to the 20 year treatment the median costs per life year 
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gained are estimated at DFL 15,729 and here 95% of all estimates lay between 
DFL 0 and DFL 50,000. 
Figure 2a Distribution of additional costs in 5000 simulations 
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Figure 2b Distribution of additional effects (in life years gained) in 5000 simulations 
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Figure 3a Dislribution of 4 years cosl-effectiveness ratio's in 5000 simulations 
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Figure 3b Dislribution of 20 years cosl-effectiveness ratio's in 5000 simulations 
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CONSEQUENCES ON A NATIONAL LEVEL 
In the SAVE trial only 7% of the patients with a myocardial infarction qualified 
for preventive treatment with captopril. However, the inclusion criteria for the trial 
were very strict. For the current analysis it is estimated that 10% of the patients 
who are admitted into hospital for myocardial infarction will be eligible for 
preventive treatment. Figure 5 illustrates that costs will increase steadily during the 
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first years after introduction of the new policy. This is due to the larger number of 
people surviving as a result of the treatment. Costs are expected to remain 
increasing until a steady state is reached. If the strategy would have been 
introduced in 1994, this steady state could have been reached around the year 
2035. In that year about 37,000 patients would be treated with captopril and each 
year 2,825 life years would be gained. On a national level the annual additional 
costs of preventive treatment would eventually amount to about DFL 42 million. If 
not 10%, but 20% or even 30% of the patients are eligible for preventive treatment 
this amount increases proportionately to DFL 84 million or DFL 125 million. 
Figure 4a Additional cosls over Ihe years by preventive Irealmenl policy wilh caplopril 
initialed in 1994 in Ihe Nelherlands 
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Figure 4b Additional life years gained over Ihe years by preventive Irealmenl policy with 
caplopril initialed in 1994 in Ihe Nelherlands 
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Discussion 
The current analysis shows that preventive treatment with captopril for 
patients with asymptomatic left ventricular dysfunction is likely to have positive 
effects. But costs will have to be made in order to gain these effects. Estimates 
based on the assumption that the results of the SAVE trial can be obtained in 
clinical practice point to a cost-effectiveness ratio of DFL 69,126 per additional 
survivor after 4 years of treatment. To give an estimation of the costs per life year 
gained the SAVE results were extrapolated to 20 years, resulting in a cost-
effectiveness ratio of DFL 15,799 per life year gained. Here, several issues warrant 
comment. 
First, the estimates in the model are surrounded by several uncertainties: cost 
data about the SAVE trial were not published, the results of the SAVE trial were 
extrapolated to the Dutch situation and a further extrapolation to a 20 year period 
was made to enable a reliable estimation of costs per life years gained. If account 
is taken of all confidence intervals surrounding the effects, treatment patterns and 
costs included into the model, an almost unlimited number of combinations of 
values for the separate items in the analysis can be made by computer simulation. 
In 5000 simulations the median cost-effectiveness ratios were compatible to those 
of the baseline-analyses: DFL 69,651 per additional survivor with a 4 year time-limit 
- with 95% of the estimates between DFL 0 and DFL 240,000 - and DFL 15,729 per 
life year gained with a 20 year time limit - with 95% of the estimates between DFL 0 
and DFL 50,000. In the univariate sensitivity analysis it is shown that the 
occurrence of clinical heart failure and the level of prevention of this occurrence by 
captopril have a major influence on the cost-effectiveness ratio. Also, the price of 
treatment with captopril turns out to be important. The cost-effectiveness ratio will 
become more favourable if the price of captopril is lowered, e.g. after expiration of 
the patent. The dosage of captopril used in the SAVE trial was rather high: 79 % of 
the patients in the captopril group reached the target dosage of 150 mg per day. If 
preventive treatment with captopril is introduced with a lower standard dosage this 
may have a favourable effect on the cost-effectiveness ratio. However, such a 
lowering in dosage could also change the effects of treatment, thereby changing 
the cost-effectiveness ratio. 
Secondly, the extrapolation of the results of the SAVE trial to a 20 year period 
is based on the assumption that the level of medical care will remain unchanged 
during this period. New technologies and treatment policies may have their 
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influence both on costs and effects during this period. The effect of this influence is 
unknown. 
Thirdly, it should be noted that if preventive treatment is introduced on a wide 
scale the cost-effectiveness may be less favourable, because not all patients will 
be selected according to the strict inclusion criteria of the SAVE trial.4 
Fourthly, the current analysis does not take effects on the quality of life and 
on indirect costs into account, because no data were available on these items. By 
reducing the number of patients with clinical heart failure, captopril, especially in 
the more severe stages, may have an important effect on the quality of life of the 
patient population involved. In the 20 year analysis the number of (undiscounted) 
life years spent in NYHA class IV is reduced by 7.7%, in NYHA class III by 9.2%, 
and in NYHA class II by 10.5%. 
Finally, the current analysis is only valid for patients with asymptomatic left 
ventricular dysfunction after myocardial infarction, one of the major risk factors for 
clinical heart failure. Alternative preventive strategies may consist of treatment of 
all patients with acute myocardial infarction or of all patients with asymptomatic left 
ventricular dysfunction. Whereas the CONSENSUS-II trial did not show an 
improvement in survival after the use of ACE-inhibitors in an unselected patient 
population after myocardial infarction, the GISSI-3 and the ISIS-4 trial did show a 
decrease in mortality.'4.25.26 The ISIS-4 trial, which included more than 58,000 
patients, showed that 1 month treatment with captopril, in a lower dose (maximum 
100 mg per day), started within 24 hours of the onset of symptoms of suspected 
acute myocardial infarction may lead to a significant reduction in 5-week mortality .. 
The benefit of 4.9 fewer deaths in 5 weeks (and 5.4 fewer deaths in 1 year) per 
1000 patients treated with 1 month of captopril that was seen in the ISIS-4 trial, 
exceeds the benefit of 4.2 fewer deaths in 4 years per 1000 continuously treated 
patients seen in the SAVE trial. However, these two patient populations are not 
completely comparable. Patients in the ISIS-4 trial were unselected, whereas 
patients in the SAVE trial had a proven left ventricular dysfunction. Further 
research will have to show which dosage, moment of initiation of therapy and 
duration of treatment is most cost-effective in patients with a recent myocardial 
infarction. In contrast to the previously mentioned trials, the SOlVO Prevention trial 
concentrated on the effect of ACE-inhibitors in patients with asymptomatic left 
ventricular dysfunction who did not experience a recent myocardial infarction. This 
trial showed an effect on the occurrence of symptomatic heart failure but no 
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significant effect on the cardiovascular death rate.s Probably, the screening that is 
necessary to find symptomless patients without overt risk-factors in the general 
population, like the patients included in the SOL VD Prevention trial, will make the 
cost-effectiveness of this treatment policy less favourable than the treatment of 
patients who are at-risk for a decrease in left ventricular function because they 
recently experienced a myocardial infarction. 
In conclusion it can be stated that, if only the effects are taken into account, 
all signs seem to be in favour of the introduction of preventive treatment of patients 
with asymptomatic ventricular dysfunction after an acute myocardial infarction in 
the Netherlands. In addition to the health care aspect, preventing or delaying the 
onset of heart failure, the strategy shows positive short-term and long-term effects 
on survival. If the positive effects are related to costs the picture is less favourable. 
But, even though the cost-effectiveness of only few preventive treatments was 
analysed for the Netherlands, most of them were shown to be less cost-effective. 
For the Netherlands the costs of screening for cervix carcinoma are estimated at 
DFL 24,000 per life year gained, and of cholesterol lowering therapy for men with 
cholesterol level above 8 mmolll at about DFL 30,000 per life year gained:'·28 
However, the costs of screening for breast cancer are lower than the amount 
estimated here: DFL 7,650 per life year gained.'· 
Health care authorities will have to decide whether the current cost-
effectiveness ratio is favourable enough to warrant introduction of preventive 
treatment without additional trials focusing on the gathering of data on costs and 
effects specific for the Dutch situation and whether they can afford the additional 
costs involved in the new strategy that could amount to up to DFL 42 million per 
year: 10.3 percent of the amount spent on heart failure in 1988. 
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PLANNING OF NEONATAL ECMO FACILITIES' 
Summary 
This chapter illustrates the use of a model, constructed in an universally 
available spreadsheet programme, in the planning of the number of neonatal 
ECMO facilities. For any number of patients presented for treatment in a region 
annually and any number of ECMO facilities the number of patients that will have to 
be referred to facilities abroad is estimated in a microsimulation model. The input of 
the model consists of the number of ECMO facilities, the number of patients 
presented annually, the duration of treatment and the dale that patients are 
presented for ECMO treatment. To illustrate the method, the Dutch situation in 
1992 (29 patients treated in 3 facilities) was described and compared to several 
future scenarios. In the main future scenario it is assumed that the number of 
patients will increase to 56 patients per year. The model shows that no additional 
ECMO facilities are necessary in the Netherlands, if between two and three 
referrals to centres abroad are acceptable and feasible. In that situation it is 
expected that on 21 occasions two patients will be treated simultaneously, for a 
total of 79 days. On 10 occasions all three facilities will be occupied at the same 
time, for 20 days in total. During 201 days at least one of the facilities will be 
occupied. Although the results of the simulation are presented for the Netherlands, 
they are generally applicable to any region in any country with similar 
characteristics with respect to neonatal ECMO. For other regions the method is 
applicable, but the results may change. 
Introduction 
Extracorporeal membrane oxygenation (ECMO) is one of the new technologies 
in neonatal intensive care. It is potentially life saving for neonates with reversible 
• Based on: Michel BC, Staveren RJE van, Geven WB, Hout SA van. Planning of neonatal ECMO facilities. 
Submitted. 
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respiratory diseases due to various causes. By temporarily taking over the 
oxygenation it can give diseased lungs opportunity to recover and it can avert the 
pulmonary complications that frequently occur in prolonged high pressure ventila-
tion. However, ECMO itself may induce complications, most notably bleedings due 
to systemic heparinisation.'·2 Therefore, treatment is limited to those who are 
thought to have a high risk of death wilh conservative treatment and a low risk of 
complications with ECMO. 
The introduction of ECMO was realised differently in various countries. In the 
United States ECMO already is an accepted form of therapy for the above 
mentioned patient population.3•4 In Europe ECMO was introduced more slowly. 
Since 1987 ECMO centres have been founded in Germany, France and Sweden."·6 
In the United Kingdom ECMO was introduced recently in the context of a 
randomised controlled trial, the results of which are not available yet.' In the 
Netherlands the attitude towards neonatal ECMO has also been reserved. At the 
moment there are three centres, all waiting for a definite decision on their status by 
the health care authorities. 
Once health care authorities approve of ECMO they also have to decide on the 
number of ECMO facilities that are necessary to provide adequate care. 
Additionally, in a region where ECMO already is an established therapy it may be 
necessary to adjust the number of ECMO facilities if changes in the indications for 
this treatment occur. It is to be expected that the required number of facilities in a 
region will depend on the number of patients who fulfil the indications for ECMO, 
the average duration of ECMO treatment and on the occurrence of simultaneous 
patient presentation. Therefore, for any given number of ECMO facilities, momen-
tary over- or undercapacity may occur. Since ECMO is a potentially life-saving 
treatment, patients who can not be treated at moments of undercapacity will either 
have to be treated conservatively - with almost certainly a lower survival probability 
- or be referred to ECMO centres elsewhere. Whether or not such referrals are 
feasible and desirable are questions that will not be addressed in this article. Here, 
we concentrate on an approach to estimate the consequences of the establishment 
of various numbers of ECMO facilities in a certain region. To illustrate this 
approach the situation in the Netherlands is analysed. But, although the results of 
this estimation are presented for the Netherlands, they are generally applicable to 
any region in any country with the same number of patients requiring ECMO 
treatment, similar indications and the same distribution of ECMO treatment 
durations. For other regions the method is applicable, but the results may change. 
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Patients and methods 
The number of ECMO facilities required to treat various numbers of patients 
was estimated by simulating ECMO treatments for 750 separate years and 
1,361,250 individual patients in a discrete event micro-simulation model.(figure 1) 
The microsimulation model has four variables as input: the number of ECMO 
facilities, the number of patients presented annually, the duration of treatment and 
the date patients are presented for ECMO treatment. The model was developed in 
an universally available spreadsheet programme (Quattro Pro for Windows version 
5.00, Borland International, Inc, 1993). First a baseline analysis was performed, 
describing the situation in the Netherlands in 1992. Then, several alternative 
scenarios were formulated to study the effects of future events on the number of 
ECMO-facilities required. Finally a sensitivity analysis for the main variable, 
duration of treatment, was performed. 
THE BASELINE ANALYSIS 
The baseline analysis was based on real data for the Netherlands. In 1992 
three ECMO centres were functioning in the Netherlands. Two centres, in 
Rotterdam and Nijmegen, included patients strictly according to a common 
research protocol, limiting treatment to neonatal patients with an AaD02 above 600 
mm Hg for 8 hours, or an Oxygenation Index above 40 in 3 to 5 consecutive blood 
gas samples within 5 hours. Patients with serious heart disease, causing an 
important right to left shunting, were excluded. 
The third programme, in Maastricht, was not bound to an official protocol. For 
this centre only data were included on the 5 patients that would have fulfilled the 
entry criteria of the research protocol used by the other two centres. Data on all 53 
patients, treated between January 1991 and July 1993, were included in the model. 
The main characteristics of these patients are described in table 1. 
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Figure 1 Outline of the simulation model 
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Implementation of trial results 
The mean treatment duration for these patients was 6 days with a minimum of 
0.6 days and a maximum of 15 days. For the model the actual distribution of these 
times was used to simulate the duration of treatment for each patient. Besides, 4 
hours were added to the duration of treatment, representing the minimum period 
necessary for cleaning and priming the equipment. Patients were said to be treated 
simultaneously if any part of their treatment period, including the cleaning period, 
overlapped with the same period of any other patient. 
Table 1 Characteristics of the 53 patients treated between January 1991 and July 1993. 
Characteristics 
Diagnosisa 
- congenital diaphragmatic hernia 
- meconium aspiration syndrome 
- other 
Gestatio0al age in weeks" 
Birth weight" 
Hours on ECMO" 
Hours between birth and ECMO" 
a number of patients (%) ; " mean ± standard deviation 
Patients I values 
16 (30.2%) 
22 (41.5%) 
15 (28.3%) 
39.4 ± 1.8 
3325 ± 523 
144 ± 73 
45 ± 55 
For each patient the model simulated the date of birth according to the monthly 
distribution of births in the Netherlands in 1992.6 Here the assumption was made 
that ECMO indications themselves show no separate seasonal trend. As a matter 
of convenience the date of birth was used as an approximation of the day of 
presentation for treatment, because patients were treated with ECMO very soon 
after birth, within on average 1.9 days (0 to 15 days). 
ALTERNATIVE SCENARIOS 
Because ECMO was a new medical treatment facility in the Netherlands, 
referral policy for this treatment was probably still suboptimal in 1992. Also, it can 
be expected that inclusion criteria and contra-indications will loosen up in time. 
Therefore the number of treatments per year will probably rise. If the 29 treatments 
in 1992 are related to the 196,734 life born babies that year,6 one ECMO treatment 
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Table 2 Results of the simulation model predicted for 1992 compared to the observed events in 1992, and several altemative scenarios. 
min = minimum; max = maximum; obs = observed events in 1992; NA = not available 
Patients referred for treatment abroad 
Occasions patients treated simultaneously (after referral): 
2 simultaneous 
3 simultaneous 
4 simultaneous 
5 simultaneous 
Days at least 1 patient is treated 
Days patients are treated simultaneously 
2 simultaneous 
3 simultaneous 
4 simultaneous 
5 simultaneous 
average 
0.3 
8.6 
2.0 
133.9 
32.3 
4.1 
1992 situation 
29 patients 
3 facilities 
min max 
0 
3 
o 
84 
11 
o 
2 
14 
5 
173 
65 
19 
obs 
NA 
10 
o 
168 
32 
o 
altemative scenarios 
56 
patients 
3 facilities 
average 
2.7 
21.3 
9.5 
200.9 
78.8 
20.4 
56 
patients 
4 facilities 
average 
0.8 
20.9 
9.4 
2.8 
199.3 
79.2 
20.8 
4.8 
56 
patients 
5 facilities 
average 
0.1 
20.5 
9.6 
3.0 
0.7 
203.5 
75.9 
21.3 
4.5 
0.8 
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in 6,784 life born babies was performed. Estimates based on the ELSO registry 
tend to a higher rate of ECMO treatments: one in 3,859 life born babies in 1988: 
Investigators in Georgia, Michigan, and OregonlWashington estimated the need for 
ECMO in the same magnitude: one in 3,717, one in 3,431 and one in 3,521 births 
respectively:·9 The need for ECMO in the UK is estimated at approximately 1 in 
5,000 life born babies.'o 
If these estimates apply to the Dutch situation - after the treatment has 
become current practice - the number of treatments will rise to 39 or maybe even to 
56 per year and of course the number of ECMO-facililies will have to be adapted to 
this new situation. In the alternative scenarios account is taken of these changes. 
Results 
THE BASELINE ANALYSIS 
In the baseline analysis 29 patients per year are treated in 3 facilities, as was 
the situation in the Netherlands in 1992. The results from the simulations are 
summarised in the first three columns of Table 2. The estimates, based on the 
microsimulation model, differ slightly from the observed figures, which are shown in 
the fourth column, but all observed figures fall within the minimum-maximum range 
of the results estimated by the model. However, caution should be taken in 
comparing the estimates with the observed figures, because no record was kept of 
the referrals to centres abroad. 
ALTERNATIVE SCENARIOS 
The alternative scenarios simulate the effects of a change in the number of 
neonatal patients annually presenting for treatment or a change in the number of 
facilities, or both. It is assumed that there is no change in the average duration of 
treatment or in the distribution of treatment durations. As may be expected, the 
number of occasions in which patients require treatment at the same time 
increases with the number of patients presented per year. 
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Figure 2 The number of occasions 2 to 6 patients will be treated at the same time 
related to the number of patients requiring treatment annually in a situation with 
an unlimited number of ECMO facilities. (no. = number; yr = year) 
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Figure 2 shows that, even if 60 patients would fulfil ECMO criteria annually, 
there would hardly ever be an occasion on which 6 patients would need treatment 
at the same time. However, the assumption that an unlimited number of facilities 
will be available does not seem realistic. It is highly probable that the number of 
treatment facilities will be limited, and that consequently some patients will have to 
be referred to facilities outside the region (or be treated conservatively). Depending 
on the number of facilities and the number of patients annually requiring treatment, 
it is estimated that between 0 and 30 patients will have to be referred to facilities 
outside the region.(figure 3) If only one facility is established, sometimes as many 
as 50% of the patients presented to that facility will have to be referred. In figure 4 
the number of occasions that patients will be treated simultaneously is shown for 2 
to 60 patients requiring treatment annually and for 2 to 5 facilities. 
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Figure 3 The percentage of patients that will have to be referred to ECMO centres 
outside the region, if 1 to 5 facilities are available in the region and 1 to 60 
patients require treatment annually. (perc. = percentage; no. = number; yr = 
year) 
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Facing an increase to 56 patients annually, Dutch health care planners can 
decide to leave the number of facilities unchanged or expand to 4 or 5 facilities. 
Table 2 shows the consequences of these scenarios. An expansion from 3 to 4 
facilities will diminish the number of referrals from 2.7 to 0.8 patients on average. It 
is expected that all 4 facilities will be occupied at the same time during 4.8 days per 
year. A further expansion to 5 facilities decreases the number of referrals even 
more, to only 0.1 patients. The disadvantage of such a policy is that the fifth facility 
will be occupied for only 0.8 days per year. Of course in reality the occupation of 
facilities will be more evenly distributed, due to the geographical spread of the 
facilities. If the presentation of neonates is spread evenly over the facilities, the 3 
facilities in the baseline analysis will on average be occupied for 45 days per year. 
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Figure 4 The number of occasions 2 to 5 patients will be treated simullaneously, if 2 to 5 
facilities are available, related to the number of patients annually requiring 
treatment. Patients that are referred to centres outside the region are included in 
the number of patients annually requiring treatment but excluded from the 
patients treated simullaneously. (no. = number; yr = year) 
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SENSITIVITY ANALYSIS 
If the average duration of ECMO treatment is increased by one (16.7%) or two 
days (33.3%), while ils distribution remains unchanged, the average number of 
referrals to centres outside the region in the 1992 situation increases to on average 
0.4 patients per year, an additional 33%, or 0.5 patients, an additional 67%, 
respectively.(table 3) However, ali changes in the average referrals found in the 
sensitivity analysis fali within the range of referrals presented in table 2. 
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Table 3 Results of the sensHivily analysis for the increase in the duration of treatment in the 1992 situation, and several altemative 
scenarios 
1992 situation altemative scenarios 
29 patients 56 patients 56 patients 56 patients 
3 facilities 3 facilities 4 facilities 5 facilities 
Increase in the duration of treatment in days +1' +2' +1 +2 +1 +2 +1 +2 
Patients referred for treatment elsewhere 0.4 0.5 4.0 5.7 1.1 0.9 0.2 0.4 
Occasions patients treated simultaneously (after referral): 
2 simultaneous 9.0 10.4 20.4 20.2 20.7 20.6 20.9 20.3 
3 simultaneous 2.5 3.3 11.7 13.9 11.3 12.5 11.5 12.4 
4 simultaneous 4.0 4.9 3.6 5.0 
5 simultaneous 1.0 1.2 
Days at least 1 patient is treated 150.2 166.6 219.8 238.7 224.7 248.7 227.1 241.7 
Days patients are treated simultaneously 
2 simultaneous 37.0 48.3 89.3 97.4 86.2 92.6 88.9 93.4 
3 simultaneous 5.9 8.6 28.4 37.0 28.8 33.6 27.9 37.6 
4 simultaneous 7.7 8.6 6.8 9.9 
5 simultaneous 1.1 2.0 
a +1 = an increase of 1 day; b +2 = an increase of two days 
Chapter 6 
DISCUSSION 
Although the planning of all health care facilities is recommendable, the 
planning of ECMO facilities is particularly important since the patients involved can 
not be placed on a waiting list. Patients who can not be treated because of a 
shortage in facilities in the region will have to be treated conservatively or be 
referred to other regions. Planning is necessary not only when ECMO is introduced 
in a region but also when changes in the number of patients requiring ECMO 
occur. Such changes, both increases and decreases, could occur through changes 
in the indications after publication of the results of the randomised trials that are 
currently in progress, through changes in the alternative treatments and through 
improvements in the technique.',l1,12 An increase in the annual number of patients 
may lead to higher levels of occupation of the facilities, causing an increase in 
referrals to facilities outside the region. If the number of ECMO facilities is 
subsequently increased the number of patients for whom facilities have to be found 
outside the area decreases. But, if too many facilities are established, money will 
be spent on facilities that will be left unoccupied for most of the year. A decrease in 
the number of patients will lead to structural overcapacity. Such overcapacity may 
loosen up criteria for ECMO treatment, causing an increased use by patients who 
do not need ECMO to survive, which in turn decreases the cost-effectiveness of 
the technology. Careful planning of the number of facilities may prevent these 
effects. 
Planning problems in which random processes playa major role, like the 
presentation of ECMO patients, can be partially solved by microsimulation models. 
Of course models are abstract representations of reality, and, as stated by Feest 
and Harrison, they are only as good as the data fed into them." But, although they 
have their limitations, they provide information that can be used in the planning of 
health care facilities. Most of the planning in health care with the aid of 
microsimulation was done for renal services and hospital bed requirements'··'9 
Unfortunately, the results were mainly published in journals specialised in 
operational research, thereby staying out of focus for most health care 
workers.16,17,18.20 
The microsimulation model for the planning of ECMO facilities shows that in 
the Netherlands - if there is no change in the average duration of treatment - an 
increase to 56 patients a year can take place without an increase in ECMO 
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facilities, if between two and three referrals to centres elsewhere are accepted and 
feasible. The acceptability or feasibility of these referrals turn out to be a crucial 
point in the planning, because it is unknown who is to decide on these issues. If 
these referrals are not accepted or not feasible, an increase in facilities has to be 
balanced against an investment in facilities which will not be occupied frequently. 
The model also shows that even after an increase to 56 patients per year the 
marginal contribution of a fifth facility is very small. Due to the geographical spread 
of facilities and the patients the occupalion may increase, but this increase will be 
at the expense of the occupation of the other 4 facilities. 
In countries with large differences in the geographic distribution of patients 
requiring ECMO treatment, due to transport problems, geographic remote areas or 
non-uniformity of the patient distribution, the model can not be applied to estimate 
the number of ECMO facilities required on a national level, but it can be used to 
estimate the need for ECMO facilities in smaller sub-regions with a homogenic 
patient distribution. For the Netherlands, the geographical distributions of facilities 
and patients are not too important for planning purposes, because it is a small 
country and newborn babies are relatively easy transported in ambulances and 
helicopters. In fact, specialised neonatal care in the Netherlands is organised on a 
national rather than on a regional basis, with a central co-ordinating system for the 
occupation of neonatal facilities. 
The current study shows that it is possible to plan the number of ECMO 
facilities required in a region with relative simple tools. Such planning may help 
ECMO centres in their decision whether or not to invest in extra facilities in a 
changing field. The study also shows that the acceptability and feasibility of· 
referrals to centres outside the region - or abroad - is an important issue which 
European health care planners will have to consider. 
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DISCUSSION AND CONCLUSIONS 
In the previous chapters several practical applications of mathematical-
statistical modelling techniques in Medical Technology Assessment were 
presented. 
The use of a model in the preparatory phase of a ReT was illustrated with 
three examples. In the first example the whole study was modelled in order to find 
the optimal design of the ReT, in the second example a diagnostic tool was 
developed with modelling techniques. This tool was subsequently used in the third 
example, in which the most cost-effective diagnostic strategy to be included in a 
ReT was selected from a large amount of possible strategies. 
In the first example a model was built to study the feasibility of the 
introduction of helicopters with medical crews for seriously injured accident victims 
in the Netherlands (chapler i).' The introduction of these helicopter "trauma teams" 
was surrounded by a (rather polarised) discussion focusing on the costs and 
effects of the helicopter service itself. However, the formal modelling of the problem 
and the subsequent scenario analysis showed that not so much the uncertainty 
surrounding the cosls of the helicopter service, bul more so the uncertainty 
surrounding the gain in survival from the service and the costs of hospital treatment 
for seriously wounded trauma victims playa decisive role in delermining the cost-
effectiveness of a helicopter trauma service. Also, the effect of the service on the 
health status of the surviving patients may be important for the cost-effectiveness 
profile of the service. However, the latter item could not be included in the model, 
because no data on this effect were available. The modelling approach was chosen 
to determine whether a clinical trial would be required, because a clinical trial in this 
field was expected to be time consuming, costly, and difficult to realise because of 
the difficulty in obtaining a reliable control group. Here, the modelling approach did 
not lead to a definite conclusion on the cost-effectiveness of the service, but led to 
a recommendation to focus further research on specific items. It also showed that 
there was no scientific basis for supporters or adversaries of the helicopter service, 
who both claimed no further research was necessary because the service 
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obviously would - respectively wouldn't - be cost-effective, to sustain either claim 
without a clinical trial. Therefore, eventually a clinical trial was designed and 
performed. 
The construction of a clinical decision rule for the diagnosis of pulmonary 
embolism (chapter 2) illustrates that modelling techniques can be applied to obtain 
optimal information from clinical observations and to develop diagnostic tools. The 
multivariate logistic regression model developed for the diagnosis of pulmonary 
embolism contains only 5 items - 2 items that can be obtained in the interview of 
the patient (previous deep venous thrombosis and recently developed or worsened 
cough), 2 items related to the physical examination (wheezing and body 
temperature above 37"C) and 1 item containing a qualitative description of the 
standard diagnostic test for these patients (multiple defects on the perfusion 
scan)! If no modelling technique would have been used, only the clinical 
assessment of the physician would have been available to assess the probability of 
pulmonary embolism without further diagnostic testing. The final model showed a 
better sensitivity and specificity than the clinical assessment by the physician 
(before lung-scanning). Microsimulation showed that models based on the selected 
combination of variables tended to be fairly robust. But, even though the sensitivity 
and specificity of the model seem favourable in the derivation phase presented in 
chapter 3, if the model is to be used not only for analytic purposes but also as a 
diagnostic tool in clinical practice it will still have to prove its usefulness in a 
prospective validation phase. There are two main reasons why the clinical decision 
rule may not perform as well as expected in this prospective validation phase, and 
eventually in clinical practice. First, physicians may score the items included in the 
model differently if they know the items will have a significant contribution to the 
result of the clinical decision rule. In other words they may - subconsciously - try to 
direct the outcome of the decision rule towards their own intuitive opinion. 
Secondly, a change in distribution of the variables and their outcomes in the future 
patient popUlation may lead to invalidity of the rule. This may especially be the 
case for rules based on small patient populations. 
The chapter concerning the evaluation of the cost-effectiveness of alternative 
strategies (chapter 3) shows that computer modelling technology can help to 
choose the most cost-effective strategy from more than 10,000 possible diagnostic 
strategies. Without the use of modelling techniques only the analysis of a few, 
predefined, diagnostic strategies would have been possible, whereas now an 
indication can be given of the costs and effects of the whole range of possible 
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diagnostic strategies. Data on sensitivity and specificity of several new diagnostic 
tests for pulmonary embolism or venous thrombosis were obtained from a 
prospective cohort study in 452 Dutch patients and incorporated in a decision tree 
model. The decision tree model was built in a spreadsheet programme and Bayes' 
theorem was used to combine the sensitivity and specificity of the separate 
diagnostic tests into a combined sensitivity and specificity for the combination of 
tests.3.4.5 The main assumption that had to be made in the analysis - for technical 
reasons - was that of the conditional independency of the test results. In this case, 
the assumption did not seem to have large effects since the application of the 
optimal strategy to the original database did not lead to results that were very 
different from those predicted by the model. However, further research into this 
field should be done to see whether simple methods can be found to analyse 
strategies containing tests with dependent results in a similar way. In a subsequent 
RCT the costs and effects of the diagnostic strategy selected by modelling may be 
prospectively compared to those of the prevailing strategy. 
The use of modelling techniques as substitute for (parts of) trials that are 
thought to be unethical, unfeasible or impossible was illustrated with an example in 
which the survival of the control group was modelled, because of the absence of a 
contemporary control group. This example (chapter 4) shows that modelling 
permits reliable evaluation of medical technologies in this situation. In the cost-
effectiveness analysis of liver transplantation the alternative would have been 
either to conduct a randomised controlled trial, which was thought to be unethical 
because liver transplantation was already assumed to be effective abroad, or to 
use a historical control group. The optimal solution for the assessment of the 
effectiveness of transplantation was found in the use of historical data incorporated 
in a Cox regression model. In the analysis, Cox regression models were used to 
predict survival probability for each patient as it would have been without 
transplantation.' However, it should be kept in mind that only models based on 
patients comparable to the patients analysed and models from countries and times 
with a level of care similar to the current level of conservative treatment can be 
used to replace a contemporary control group. 
Chapter 5 shows that modelling techniques can be used for the extrapolation 
of the effects of a clinical trial, in this case to another country and another time 
perspective. The effects of ACE-inhibitors on cardiovascular morbidity of patients 
with a-symptomatic heart failure after a myocardial infarction, which were assessed 
in a North American trial,7 were extrapolated to the Dutch situation and to a follow-
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up of 20 years in a Markov model. 4,8,9 Because no data on costs were published for 
the original trial the trial was also complemented with cost data specific of the 
Dutch situation. Although ACE-inhibitors were used as a preventive therapy, a RCT 
was feasible because the treatment showed effects within a reasonable time-
period. In this example the alternative would have been to repeat the clinical trial as 
a cost-effectiveness trial in the Netherlands, which would have been costly, time-
consuming, and - as the results of the modelling analysis show - probably 
unnecessary. 
In the extrapolation and complementation of the trial results many 
uncertainties had to be incorporated into the model. The effect of these 
uncertainties on the final outcome was analysed with a multivariate sensitivity 
analysis in a microsimulation model,1O,11,12.13 which was superimposed on the 
Markov model. Here also the assumption of independency of the effects of the 
separate variables had to be made for technical reasons. The sensitivity analysis 
led to a frequency distribution of cost-effectiveness ratios, which included the 
"worst outcome scenario", combining maximum costs with minimal effects, health 
care planners might be interested in before approving the introduction of such 
preventive treatment. This shows that multivariate sensitivity analysis, which used 
to be almost impossible in situations where more than a few variables were 
deemed to be important, can easily be obtained by modelling techniques, under 
the assumption of independency of the effects of the separate variables. 
The use of modelling techniques to predict the consequences of the 
implementation of a new technology was illustrated with examples on the 
assessment of macroeconomic consequences of the introduction of ACE-inhibitors 
(chapter 5) and on the planning of ECMO facilities (chapter 6). 
The use of modelling in the analysis of the macro-economic consequences of 
the introduction of a new technology was described in the chapter on the 
introduction of preventive treatment with ACE inhibitors (chapter 5). The Markov 
model indicates the nation-wide annual additional costs of this treatment will 
probably increase during the first years after the introduction of ACE-inhibitors as 
preventive therapy,4,8,9 until, after some 40 years, a steady state might be reached 
in which the annual additional costs amount to approximately 42 million Dutch 
Guilders. This last figure should not be taken as the absolute truth but only as a 
frame of reference, because new developments and therapies during those 40 
years are, of course, not included in the model. Despite these uncertainties, 
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modelling may give an impression of the nation-wide consequences even before 
the treatment is implemented, thereby saving time and money. 
Finally, the example on the planning of neonatal ECMO facilities shows that 
an efficient planning of health care facilities can be supported by modelling 
techniques. The model, a microsimulation,4.13.14 describes the duration of ECMO 
treatment, which was randomly drawn from the obseNed frequency distribution of 
treatment durations in the Netherlands, for different numbers of patients requiring 
treatment annually and for different numbers of treatment centres. With the model 
the numbers of patients that will have to be referred to centres outside the region 
are assessed. The model showed that in the Netherlands no additional ECMO 
facilities will be needed in the near future, if between 2 and 3 referrals to centres 
abroad are thought to be acceptable and feasible. This example illustrates the 
potential role of modelling techniques in the planning of health care facilities. 
Whereas such techniques are commonly used in operations research for industrial 
purposes, their use in health care has hitherto been limited. However, with a more 
formalised planning uneconomic proliferation of health care, facilities may be 
prevented and a more efficient level and distribution of care may be obtained. 
In this thesis the place of mathematical-statistical models in medical 
technology assessment is discussed and illustrated with examples. A large 
advantage of modelling techniques over RCTs not discussed in detail in the 
previous chapters, is that they allow for a better incorporation of rare events than 
RCTs do. For example, in the evaluation of a relatively inexpensive new therapy for 
oesophagus varices one liver transplantation occurring (by chance) in one of the 
arms of the RCT may have a large influence on the costs of that arm, whereas by 
modelling the occurrence of liver transplantation may be brought to realistic 
proportions in both treatment groups. 
137 
Discussion and conclusions 
Figure 1 The 95% confidence intervals for lwo medical lechnologies A and B. 
Technology A can be called cosl-effective despite the large confidence 
interval, whereas no conclusions can be drawn about lhe cosl-effectiveness 
of lechnology B. 
additional costs 
A 
Limit cost-
effectiveness 
additional effects 
The overview thus far gave an optimistic impression of the many and varied 
opportunities modelling techniques may offer in this field. However, a warning 
should be given: models tend to start a life of their own and may suggest a 
reliability that does not exist: models can never be more reliable than the data they 
are based on. In addition to this there are other limitations to modelling techniques: 
• Unfortunately, in general, modelling is viewed with more suspicion than ReTs, 
because of the incorporation of data from different sources which introduces 
additional bias and uncertainty. However, figure 1 illustrates that a large 
uncertainty margin need not represent a problem for decision making as long as 
every point within the uncertainty area surrounding the cost-effectiveness of the 
technology is on one side of the line representing the societally acceptable level 
of cost-effectiveness (situation A).15 In contrast, a much smaller 95% confidence 
interval which passes the limit of cost-effectiveness (situation B) can definitely 
prohibit the drawing of conclusions from assessment B. Therefore, as long as 
the limit of cost-effectiveness is not passed - and as long as the decision based 
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on the analysis remains unaltered - even modelling techniques leading to large 
uncertainty margins may still return useful results. 
• Modelling techniques can only be used if enough representative data are 
available. Even though in theory an unlimited number of wild guesses can be 
made and incorporated into a model, in practice a majority of the assumptions 
incorporated into a model need some basis in reality to give the model validity . 
• Technical limitations mainly lay in the assumption about conditional 
independency of the results of tests or of the influence of variables on the 
outcome. Computer time, which used to be the main limitation to the application 
of modelling techniques, is hardly a limiting factor any more with modern 
computer facilities. 
In conclusion, it can be stated that mathematical-statistical modelling certainly 
deserves a place within the distinct phases of medical technology assessment. 
This thesis shows that modelling can lead to useful results in, amongst others, the 
design of ·trials, the assessment of the effectiveness of medical technology in 
situations where a contemporary control group is lacking, the improvement of the 
use of clinical data, the evaluation of the cost-effectiveness of diagnostic strategies, 
the complementation of trial results with cost data, the extrapolation of trial results 
to other countries and time horizons, the evaluation of macro-economic 
consequences of the introduction of medical technology and in the planning of 
health care facilities. In medical technology assessment modelling should not be 
seen as a strict replacement for randomised controlled trials. I n some situations a 
classic RCT still remains the optimal analysing technique. But in others, modelling 
may return information much faster and cheaper than a randomised controlled trial 
ever could. 
In general it should be kept in mind that the usefulness of models is limited 
through the assumptions and data included. Therefore, as a recent editorial in the 
New England Journal of Medicine on the use of models in cost-effectiveness 
studies stipulated, in the reporting of the results of a modelling analysis all data, all 
assumptions and any model used should be included and explained clearly.'6 
Because of the large uncertainty margins often surrounding the outcome of 
models, the requirement to perform a detailed, preferably multivariate, sensitivity 
analysis should be added to this. 
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SAMENVATTING 
In dit proefschrift wordt de plaats van wiskundig-statistische modellen binnen de 
Medische Technology Assessment (MTA) ge'inventariseerd en besproken. MTA is 
een vorm van onderzoek waarbij de verschillende aspecten van een medische 
technologie in kaart worden gebracht om de besluitvorming omtrent die technologie 
zo goed mogelijk te laten plaatsvinden. Kosten-effectiviteitsanalyse - waarin de 
kosten die aan de technolagie verbanden zijn worden gerelateerd aan de effecten 
op overleving, morbiditeit en kwaliteit van leven - vormt meestal de kern van een 
dergelijk onderzoek. Daarnaast kunnen echter oak andere aspecten, bijvoorbeeld 
op het juridische of ethische vlak, in de analyse worden betrokken. 
Vaak wordt gerandomiseerd (dubbel blind) onderzoek, waarbij de te 
onderzoeken technologie wordt vergeleken met de beste op dat moment gang bare 
behandeling, aanbevolen als de meest geschikte methode om de kosten en 
effecten van een medische technolagie aan elkaar te relateren. Dergelijk 
onderzoek is echter niet altijd mogelijk of wenselijk. Indien er (nog) geen 
gerandomiseerd onderzoek kan plaatsvinden kunnen modelleringstechnieken 
worden gebruikt om toch een indruk van de kosten en effecten van de technologie 
te krijgen. Deze technieken kunnen in aile fasen van MTA worden toegepast: bij de 
voorbereiding en ontwikkeling van een kosten-effectiviteitsstudie, als vervanging 
van (gedeelten van) het gerandomiseerd onderzoek, om kostengegevens aan een 
gerandomiseerd onderzoek toe te voegen, bij de extrapolatie van 
onderzoeksresultaten naar een langere termijn, een ander land of een andere 
patientenpopulatie en bij de implementatie van onderzoeksresultaten. De 
verschillende toepassingen zullen hieronder kort worden besproken. 
Bij de voorbereiding en ontwikkeling van een kosten-effectiviteitsstudie kan 
modellering worden gebruikt om te onderzoeken of gerandomiseerd onderzoek 
nodig en zinvol is. Bovendien kan een indruk worden gekregen van de 
onderwerpen die in ieder geval in een dergelijk onderzoek dienen te worden 
betrokken. Deze toepassing wordt ge'illustreerd met een voorbeeld waarbij de 
kosten en effecten van de introductie van helikopters met traumateams in 
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Nederland worden onderzocht (hoofdstuk 1). In de analyse werden aile op het 
moment van het onderzoek voor Nederland beschikbare relevante gegevens 
gecombineerd in een model. Uit deze benadering bleek dat de onzekerheid 
rondom de overlevingswinst als gevolg van de helikopterservice en de kosten van 
een ziekenhuisopname voor een ernstig gewonde patient van veel groter belang 
waren voor de uitkomst dan de onzekerheid rondom de kosten van de 
helikopterservice zelf. Ook bleek dat er op basis van de beschikbare gegevens 
geen duidelijke uitspraken te do en waren over de kosten-effectiviteit van de 
service. Uiteindelijk werd derhalve besloten een experimenteel onderzoek uit te 
voeren om tot een betrouwbare uitspraak omtrent de kosten-effectiviteit van de 
helikopterservice in Nederland te komen. Door de modelmatige voorstudie was 
duidelijk dat analyse van de effecten op de overleving en de kosten van 
ziekenhuisopname een belangrijke plaats in het experimentele onderzoek 
verdienden. 
Ook kan modellering gebruikt worden om methoden te ontwikkelen die bij het 
gerandomiseerd onderzoek gebruikt kunnen worden. Deze toe passing wordt 
geHlustreerd met een voorbeeld waarin de klinische informatie die nodig is om de 
diagnose longembolie te stellen met behulp van logistische regressie wordt 
gecombineerd tot een klinische beslisregel (hoofdstuk 2). De relatief eenvoudige 
beslisregel suggereerde een betere sensitiviteit en specificiteit dan de klinische 
indruk van de arts en kan, na een prospectieve validatie, mogelijk zelfs in de 
praktijk worden gebruikt als een diagnostische test. In een gerandomiseerd 
onderzoek naar de beste strategie bij de diagnostiek van longembolieen kan de 
beslisregel worden gebruikt om klinische gegevens in het onderzoek te betrekken. 
Bij het selecteren van de strategieen die in het gerandomiseerde onderzoek 
worden opgenomen maakt modellering, in combinatie met een cohort-onderzoek, 
een snelle evaluatie van de kosten en effecten van een groot aantal strategieen 
mogelijk. Dit wordt geHlustreerd met de evaluatie van de kosten en effecten van 
diagnostische strategieen bij patienten met een mogelijke longembolie (hoofdstuk 
3). In dit voorbeeld worden, in een combinatie van een besliskundige analyse en 
een prospectief cohort-onderzoek bij 452 patienten, de kosten en effecten van aile 
mogelijke diagnostische strategieen (meer dan 10.0001) met elkaar vergeleken. De 
evaluatie van een dergelijk groot aantal strategieen zou met behulp van 
gerandomiseerde trials natuurlijk onmogelijk zijn geweest. Uiteindelijk kan de 
meest kosten-effectieve strategie, geselecteerd met deze methode, vergeleken 
worden met de gang bare strategie in een gerandomiseerd onderzoek. 
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Modellering kan ook gebruikt worden als vervanging van een (gedeelte van) 
gerandomiseerd onderzoek. 
Bij de kosten-effectiviteitsanalyse van screeningsprogramma's en preventieve 
behandelingen kan modellering worden gebruikt om gebeurtenissen in de verre 
toekomst of zeldzame - maar belangrijke of kostbare - complicaties in de analyse 
te betrekken. Gerandomiseerd onderzoek zou in dit geval meestal kostbaar en 
langdurig zijn. 
Bij de evaluatie van behandelingen die levensreddend kunnen zijn bij patienten 
waarvoor eigenlijk geen alternatieve behandelingsmogelijkheden bestaan, wordt 
gerandomiseerd onderzoek snel onethisch gevonden. Door modellering van de 
controlegroep kan in dergelijke gevallen toch een uitspraak gedaan worden over de 
(kosten-)effectiviteit van de behandeling. Deze toepassing wordt geHlustreerd met 
een onderzoek naar de kosten en effecten van levertransplantatie, waarbij de 
overleving van de controlegroep werd gemodelleerd met behulp van Cox regressie 
(hoofdstuk 4). Op deze wijze kon aannemelijk worden gemaakt dat 
levertransplantatie een aanzienlijke overlevingswinst kan bewerkstelligen ten 
opzichte van conservatieve behandeling. 
Naast bovengenoemde indicatie zijn ook andere toepassingen van modellering ter 
vervanging van (gedeelten van) gerandomiseerd onderzoek denkbaar. Zo kan 
modellering worden toegepast om een kosten-effectiviteitsanalyse te doen van 
technologieen die gebruikt worden bij relatief zeldzame ziekten of ziekten met een 
lage incidentie, zoals bijvoorbeeld bij de kosten-effectiviteitsanalyse van inenting 
na hondsdolheidbesmetting. 
Indien een gerandomiseerd onderzoek beschikbaar is, waarbij geen kosten 
werden verzameld, kan modellering worden gebruikt deze alsnog aan het 
onderzoek toe te voegen, zodat alsnog een kosten-effectiviteitsratio kan worden 
berekend. In dit proefschrift is deze methode toegepast bij een kosten-
effectiviteitsanalyse op basis van de gepubliceerde gegevens van het SAVE 
onderzoek, een groot Amerikaans onderzoek naar de effecten van ACE-remmers 
als preventieve behandeling na een hartinfarct (hoofdstuk 5). 
Modellering kan ook worden gebruikt om een meer betrouwbare kosten-
effectiviteitsanalyse mogelijk te maken door de extrapo/atie van de resultaten van 
gerandomiseerd onderzoek. In een model kunnen de resultaten van vrijwel 
identieke trials worden gecombineerd of kunnen de intermediaire uitkomstmaten 
van een trial (zoals het aantal maagzweren dat wordt voorkomen met een 
bepaalde medicatie) worden vertaald naar uitkomstmaten die bruikbaar zijn voor 
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kosten-effectiviteitsanalyse, zeals gewonnen levensjaren en voor kwaliteit van 
leven gecorrigeerde gewonnen levensjaren. 
In dit proefschrift wordt het gebruik van modellering bij de extrapolatie van 
onderzoeksgegevens geHlustreerd met Markov model waarmee de resultaten van 
het SAVE onderzoek (hoofdstuk 5) zijn geextrapoleerd naar Nederland en naar de 
lange termijn (van 4 jaar naar 20 jaar). Omdat in de extrapolatie werd vergeleken 
met de gang bare Nederlandse praktijk in plaats van met de oorspronkelijk 
placebobehandeling is er ook sprake van een extrapolatie van een door de 
inclusiecriteria van het onderzoek beperkte werkzaamheidsanalyse naar een 
effectiviteitsanalyse. 
Tenslo!te kunnen modelleringstechnieken ook worden gebruikt bij 
beslissingen rond de imp/emenlalie van medische technologieen. 
Onderzoeken naar de gevolgen van nationale implementatie zijn in de praktijk vaak 
kostbaar en langdurig. Bovendien is het vrijwel onmogelijk om de implementatie na 
een nationale introductie alsnog te stoppen als de resultaten ongunstig uitvallen. 
Met behulp van een Markov model werden de macro-economische gevolgen 
gedurende de eerste 50 jaar na introductie van preventieve behandeling met ACE-
remmers in Nederland geschat (hoofdstuk 5). Hoewel deze berekening natuurlijk 
met onzekerheid omgeven is, kan deze methode een indruk geven van de te 
verwachten effecten voordat daadwerkelijk introductie op nationale schaal 
plaatsvindt. 
Modelleringstechnieken kunnen ook worden gebruikt bij de planning van nieuwe 
medische faciliteiten. Het laatste voorbeeld toont aan dat met behulp van een 
microsimulatie voor ECMO-behandeling bij pasgeborenen kan worden geschat 
hoeveel kinderen er jaarlijks v~~r behandeling naar het buitenland moeten worden 
verwezen bij een bepaald aantal behandelingsfaciliteiten in Nederland (hoofdstuk 
6). Het resultaat van deze analyse is dat er in Nederland geen extra ECMO-
faciliteiten voor pasgeborenen nodig zijn als 2 tot 3 verwijzingen naar het 
buitenland per jaar acceptabel wordt gevonden. Modellering leidt hierbij sneller en 
goedkoper tot resultaten dan een evaluatie die pas plaatsvindt nadat reeds een 
groot aantal faciliteiten is opgericht. 
Bovenstaande voorbeelden tonen aan dat modelleringstechnieken, zoals 
Markov processen, microsimulatie en beslisbomen, een ruime toepasbaarheid 
hebben binnen MTA-onderzoek. Daarnaast kennen ze natuurlijk ook beperkingen. 
Deze zijn voornamelijk gelegen in de betrouwbaarheid, beschikbaarheid en 
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relevantie van de gegevens die in het model zijn opgenomen, de grate 
onzekerheidsmarge die modellering soms met zich mee brengt en in technische 
opzicht in de gecompliceerdheid van de modellering bij condition eel afhankelijke 
invloed van variabelen op de uitkomst, en - in steeds mindere mate - in de 
beschikbaarheid van computerfaciliteiten. 
De conclusie van het hier gepresenteerde onderzoek is dat er zeker een 
plaats is voor modellering in de verschillende lasen van Medische Technology 
Assessment, mits de onzekerheden en de veronderstellingen die aan het gebruikte 
model gerelateerd zijn duidelijk gedocumenteerd worden in de verslaglegging van 
de resultaten. Een uitgebreide, lielst multivariate, gevoeligheidsanalyse is daarbij 
gewenst. 
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"Would you tell me, please, which way I ought to go from here?" 
"That depends a good deal on where you want to get to," said the Cat. 
"I don't much care where ........ " said Alice. 
"Then it doesn't matter which way you go," said the Cat. 
" ..... so long as I get somewhere," Alice added as an explanation. 
"Oh, you're sure to do that," said the Cat, "if you only walk long enough." 
Lewis Carroll: Alice in Wonderfand 

